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Critical lung diseases such as acute respiratory distress syndrome (ARDS) and chronic 
obstructive pulmonary disease (COPD) are one of the leading causes of death 
worldwide. The most important component of treatment for patients with such 
conditions is mechanical ventilation. However, mechanical ventilation can also cause 
ventilator induced lung injuries (VILI). Consequently, clinicians have for many years 
been conducting extensive investigations using experimental studies in animal models 
and clinical trials in human patients in order to find safer and more effective ventilation 
strategies. To assist these efforts, engineering approaches such as computational 
modelling can also be employed to investigate and develop novel treatment strategies, 
with fewer ethical, practical and cost constraints than in vivo experiments. 
In this thesis, a state-of-the-art computational simulator of cardio-pulmonary physiology 
is used to investigate novel treatments including ventilatory strategies and drug 
interventions for critical lung disease in adults, paediatrics and neonates. First, the 
impact of a novel compound on gas exchange is evaluated in virtual patients with 
COPD and pulmonary hypertension (PH) as a complication, considering both systemic 
administration of the drug and dry powder inhalation. Next, the ability to simulate 
paediatric subjects is incorporated into the model, and a new dataset of paediatric 
ARDS patients is analysed to investigate whether, and how, more lung protective 
ventilation could be achieved in clinical practice. Subsequently, the utility of two recently 
proposed measures of VILI, mechanical power (MP) and driving pressure (∆P), as 
targets to derive maximally protective ventilator settings is tested on two cohorts of 
virtual adult and paediatric ARDS patients. Finally, initial results on the adaptation of 
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1.1. Thesis outline and main contributions 
Computational simulation offers a new approach to traditional medical research that is 
particularly well suited to investigating treatment of critical illness. Critically ill patients 
are routinely monitored in great detail, providing extensive, high quality data-streams for 
model design & configuration and patient-matching. Models based on these datasets can 
incorporate very complex representations of cardiorespiratory pathophysiology that may 
be validated against responses of individual patients, for use as investigational 
surrogates. This thesis develops a number of such models and uses them to perform 
“virtual” clinical trials of novel treatment strategies in a number of different clinical 
scenarios. 
Chapter 2 consists of an introduction to respiratory system modelling and presents the 
key concepts and background material used in this thesis. The important role of 
mechanical ventilation in managing critically ill patients in the intensive care unit is 
discussed. Previous models of the respiratory system are reviewed and the 
computational simulation platform that forms the basis for the studies conducted in this 
thesis is described.   
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In Chapter 3, the efficacy of a modulator of soluble guanylate cyclase (sGC) in COPD 
patients with pulmonary hypertension (PH) is investigated by using computer 
simulation. In this study, close matching of the simulator to data from a clinical trial on 
three COPD patients was demonstrated. The study showed that administering an sGC 
via dry powder inhalation can reduce PH without deteriorating oxygenation, particularly 
when administration is combined with exercise. 
In Chapter 4, computational modelling is used to analyse an extensive new database on 
paediatric acute respiratory distress syndrome (PARDS) patients collected by medical 
collaborators at The Children’s Hospital of Philadelphia. The results of this study 
suggest that these patients may be being routinely over-ventilated (i.e. excessive 
ventilation (low CO2) which may not be necessarily injurious, however, it increases the 
risk of ventilator induced lung injury (VILI)), and that there is scope for achieving more 
protective ventilation without compromising safe gas exchange. The results suggest that 
interventions based on (a) progressively lowering tidal volume (VT) while maintaining 
constant minute ventilation, and (b) adjusting positive end-expiratory pressure (PEEP) 
and VT to reduce driving pressure (∆P), can produce significant reductions in multiple 
key parameters associated with ventilator induced lung injury (VILI) without 
compromising safety. 
In Chapter 5, computational modelling is used to identify novel ventilatory strategies 
that minimize driving pressure, mechanical power (MP), and modified mechanical 
power (MMP) in clinical datasets from adults and children with acute respiratory distress 
syndrome (ARDS). The identified strategies were consistent within each patient group, 
and were similar in both adults and children, suggesting that protective ventilatory 
strategies derived from studies in adults may have utility in children with ARDS. This 
analysis also revealed potential problems with some currently proposed measures of 
VILI, at least in terms of their use as direct targets for optimizing ventilator settings. 
In Chapter 6, the development of the first detailed computational simulator of neonatal 
respiratory physiology in the ARDS disease state is presented. Results of matching the 
model to new patient data collected by medical collaborators at the Queen’s Medical 
Chapter 1 
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Centre in Nottingham indicate that the responses of individual neonatal patients to a 
range of different ventilator settings are accurately reproduced by the model, confirming 
its potential usefulness for investigating new therapeutic strategies. 
Chapter 7 summarises the main findings from the work conducted in this thesis and 
suggests additional work that could be performed to further develop the models and 
exploit them in future studies of novel treatment strategies for acute respiratory illness.  
1.2. Publications arising from this research 
The work contained in this thesis has been published in the following peer-reviewed 
research papers: 
1. Saffaran S, Das A, Hardman JG, Yehya N and Bates D (2017) “Development 
and validation of a computational simulator for pediatric acute respiratory 
distress syndrome patients”, in the Proceedings of 39th Annual International Conference 
of the IEEE Engineering in Medicine and Biology Society (EMBC), Jeju Island, South 
Korea. 
2. Saffaran S, Wang W, Das A, Schmitt W, Becker-Pelster E, Hardman JG, 
Weimann G and Bates D (2018) “Inhaled sGC modulator can lower PH in 
patients with COPD without deteriorating oxygenation.” CPT Pharmacometrics 
and Systems Pharmacology 2018; 7:491–498. 
3. Saffaran S, Das A, Hardman JG, Yehya N and Bates D (2019) “High-fidelity 
computational simulation to refine strategies for lung-protective ventilation in 
paediatric acute respiratory distress syndrome.” Intensive Care Medicine 2019; 1:10–
12. 
4. Saffaran S, Das A, Algarni S, Laviola M, Niklas C, Hardman JG, Sharkey D and 
Bates D (2019) “Computational simulation of mechanically ventilated neonatal 
patients in the intensive care unit” in the Proceedings of 41st Annual International 
Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Berlin, 
Germany. 
5. Saffaran S, Das A, Laffey JG, Hardman JG, Yehya N and Bates D (2020) 
“Utility of driving pressure and mechanical power to guide protective ventilator 
settings in two cohorts of adult and pediatric patients with acute respiratory 








2.1. Pulmonary physiology 
The human pulmonary system comprises all organs and structures within the body that 
play a significant role in the process of respiration i.e. the exchange of oxygen (O2) and 
carbon dioxide (CO2) with the environment in order to facilitate the production of 
energy. Lungs are surrounded by respiratory muscles which assist airflow into and out 
of the body and the pulmonary artery, vein and capillary network which transports 
blood to and from the lungs to allow for gas exchange between blood and air. Lung 
volumes and capacities describe how much air normally fills the lungs. Lung volumes 
fluctuate during the breathing cycle, as the alveoli expand and contract. There are 
various terms that are used to characterize the lung volumes and capacities in different 
points in the breathing cycle. Some of the most common lung volume terms are: 
• Total Lung Capacity (TLC) – The volume of air in the lungs upon the maximum 
effort of inspiration; 
• Residual Volume (RV) – The volume remaining in the lungs after maximal 
exhalation; 
• Tidal Volume (VT) – The amount of air a person inhales during a normal breath; 
Chapter 2 
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• Functional Residual Capacity (FRC) – The volume remaining in the lungs 
following normal expiration. 
Respiration begins at the nose or mouth, where oxygenated air is brought in. The 
trachea is the starting point to transfer the gas. It is the largest of all the airways and at 
its distal end branches into two bronchi leading to the left and right lung. Each 
bronchus progressively branches into shorter, narrower airways called bronchioles. 
Bronchioles subsequently branch into elastic cavities called alveoli. The lungs consist of 
approximately 300 million alveoli, where different gasses are transferred into and out of 
the bloodstream. The factors that determine the gas flow to and from the alveolar units 
are the airway resistances and the pressure gradient between the mouth and the lungs. 
Each alveolus has a thin surface surrounded by a network of capillaries. From this point, 
O2 is diffused to the blood and CO2 is diffused to the alveolar units. Inhaling 
oxygenated gas provides higher partial pressure of oxygen (PO2) inside alveolar 
compartments than in the corresponding capillaries. This pressure gradient moves O2 
across the alveolar membrane into the blood. The same process happens for CO2 in the 
opposite direction since the partial pressure of carbon dioxide (PCO2) is higher in the 
capillaries than alveoli. The diffusion of gasses continues until the partial pressures in 
both environments are in equilibrium. The rate of diffusion is different for different 
types of gas due to their individual properties. The pulmonary capillaries with 
oxygenated blood mix into the pulmonary vein and consequently converge to the heart 
where oxygenated blood is pumped into systemic circulation. 
Due to higher solubility of CO2, blood carries it in dissolved form while only a relatively 
small portion of the total blood oxygen content is dissolved (reduced solubility of O2). 
Consequently, O2 is mostly carried in the blood as oxyhaemoglobin which is formed by 
the combination of haemoglobin with oxygen. As CO2 is more soluble and more 
chemically reactive, it is present in a higher quantity in blood. Moreover, the dissolved 
CO2 reacts with water to form H2CO3 which accordingly can be dissociated to H+ and 
bicarbonate (HCO–3), this reaction is reversible. This makes CO2 a major regulatory factor 
for controlling pH in the blood. An elevated level of CO2 in the blood leads to higher 
Chapter 2 
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amounts of H+ ions which subsequently makes the blood more acidic (reducing the 
pH). Raised amounts of HCO–3 cause a reduction in the available H+ ions, which 
increases pH (making the blood more alkaline). The kidneys also play a role in regulating 
and maintaining the pH balance in the human body by absorbing HCO–3 and producing 
H+ ions. 
Information regarding the distribution of gas exchange in the lung can provide 
substantial insight regarding any underlying pathology. Adequate ventilation in the 
presence of sufficient perfusion results in efficient gas exchange. This matched 
occurrence of ventilation and perfusion can be represented by the V/Q 
(ventilation/perfusion) distribution. A V/Q ratio of 1 denotes that the ventilation and 
perfusion are matched whereas values higher than 1 indicate areas of the lung with good 
ventilation but poor perfusion, and values less than 1 indicate areas with low ventilation 
but adequate perfusion. Extreme cases are where there is ventilation with no perfused 
blood (dead space); and where there is perfusion but no ventilation (shunt). Important 
information about the state of the lungs can thus be extracted from the levels of V/Q 
mismatch. However, the involved time-varying parameters such as cardiac output and 
minute ventilation complicate accurate measurement of the V/Q imbalance. 
2.2. Mechanical ventilation 
Since the appearance of the very first satisfactory mechanical ventilator in 1929 (i.e. the 
“Iron Lung” [1]), mechanical ventilation has been one of the most frequent life support 
therapeutic intervention for critically ill patients. It is also the most important 
therapeutic intervention for patients with respiratory failure in intensive care units 
(ICU’s) [2, 3]. 
A number of different studies have indicated that mechanical ventilation along with 
suitable ventilator settings and interventions (i.e. protective ventilation) can reduce 
length of ICU stay, mortality, and associated healthcare costs in patients with acute lung 
injury (ALI) and acute respiratory distress syndrome (ARDS) [2, 4–7]. However, 
clinicians administering mechanical ventilation encounter many challenges in 
determining the safest and most effective ventilator management strategy due both to a 
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lack of comprehensive guidelines and the fact that the settings for each patient should 
ideally be set based on their individual characteristics and disease state [3, 8]. State-of-
the-art advanced mechanical ventilators can aid clinicians in this task by providing 
decision support capabilities and taking advantage of automatic feedback to adjust 
mechanical ventilator settings based on patient data [9, 10]. It should be noted, however, 
that these systems rely solely on measured patient outputs and consider predefined 
ranges of mechanical ventilator settings, and not the individual patient physiology and 
underlying disease [9, 10]. Currently, clinicians in the ICU aim to keep the patient within 
a respiratory comfort region while maintaining adequate oxygenation based on general 
available guidelines [11, 12]. Also, the physicians’ personal experience often plays an 
important role in choosing the best set of ventilator settings [13]. 
Inappropriate ventilation strategies could result in potentially unsafe treatment and 
cause ventilator-induced lung injuries (VILI). The concept of VILI was first introduced 
by Mead et al. in 1970 [14]. The term VILI refers to the lung injury arising due to 
exposure to injurious ventilation contributions such as high airway pressures resulting in 
barotrauma, over-distension of alveoli, repeated alveolar collapse and expansion 
(atelectotrauma) and localised injury and inflammation due to intubation. These high 
pressures and volumes adversely impact the operation of the respiratory system. As a 
result, in spite of its important life-saving role in intensive therapy unit, mechanical 
ventilation can potentially cause prolonged ICU stay, a range of lifelong lung injuries 
and even multiple organ failure and death [13, 15, 16]. A study on a total of 5183 
mechanically ventilated patients by Anzueto et al. [17] revealed that VILI was diagnosed 
in 154 patients (2.9%). Furthermore, another study by Tejerina et al. [18] showed a 
higher rate of incidence (15%) in a larger cohort (2897 patients). Considering the 
sizeable number of patients undergoing mechanical ventilation (e.g. more than 69k 
patients in the UK in 2012 according to the Case Mix Programme), thousands of 
patients are potentially suffering from VILI each year. 
Therefore, the main challenge when mechanically ventilating critically ill patients can be 
summarised as maintaining adequate gas exchange whilst avoiding VILI [19, 20]. Over 
recent years, numerous clinical trials have been conducted aimed at exploring 
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mechanical ventilation strategies that could reduce the risk of VILI. Different 
approaches including the use of low tidal volumes, high PEEP, high-frequency 
oscillatory ventilation, etc. have been investigated to reduce the risk of lung injury for 
mechanically ventilated patients [4, 6, 14, 20–24]. However, although considerable 
progress has been made, there is still significant uncertainty about which strategy will 
minimize VILI for any given clinical scenario, and the mortality rate for ARDS and ALI 
patients receiving mechanical ventilation remains high (30-40%) [14, 25]. Further 
improvements in minimising VILI could potentially be achieved by incorporating 
tailored strategies based on an individual patient’s pathophysiology. However, many 
challenges such as the lack of accurate comprehensive patient data at the bedside and 
the complexity of the underlying pathophysiology hinder clinicians from considering 
individual patient information when making decisions for ventilator management [14, 
25–29]. 
2.3. Previous models of the pulmonary system 
Engineering approaches such as computational modelling can be employed in order to 
create an easier route to development of bespoke treatments, with fewer constraints 
than in vivo experiments. The real-life processes can be reproduced and better 
understood by means of modelling. It also can be engaged in testing and evaluating 
hypotheses [30]. However, the enormous requirements made on the capability of the 
models designed to be used in clinical environments has raised high-maintenance 
expectations on validation of such models with safety-critical applications. 
Consequently, the models need to be validated by means of promising methods to 
guarantee the essential robustness and earn the required reliability, stability and 
credibility in this field. [31–33]. 
Formulating the theoretical principles of the respiratory system such as relationships in 
gas exchange and ventilation paved the way for the mathematical and computational 
modelling. The efforts began by studies of acidosis as well as the equilibrium between 
oxygen and carbonic acid in the blood [34–36]. The work continued in this area 
resulting in a deeper theoretical understanding of the underlying physiology and 
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introducing different relations and equations such as Henderson-Hasselbalch equation, 
Van Slyke equation, etc. which are the cornerstone of the present-day studies of 
pulmonary physiology [37–45]. 
Computational modelling of respiratory system has been involved in different studies 
over the past years, improving the research outcome in the field [46–52]. It was not until 
the middle of the twentieth century that the advances in engineering methodologies 
along with the developed mathematics of respiration resulted in the development of the 
first simple models of the respiratory system. The model established by Grodins and 
colleagues [53, 54] uses differential equation to illustrate the relationship among a single-
compartmental lung with constant volume, blood and tissue. The model describes the 
effect on O2-CO2 interaction by the chemoreceptors, chemical buffering etc. In spite of 
its simplicity and deficiencies such as missing dead space (DS), this model has been the 
base of many other works [55–58]. 
Multi-compartmental models are able to describe the respiratory system in more details. 
A detailed model is more effective when studying features such as compliance, 
resistance, ventilation-perfusion distribution and delivery of gas across the whole lung. 
It also offers the ability to consider inhomogeneity in the lung. Accordingly, many 
studies in the literature have taken advantage of this feature in their models. In such a 
model by Hinds [59, 60], ventilation/perfusion distribution and variations of volume 
and pressure within the lung were illustrated. The effect of series dead space and its role 
in ventilation is explored by another work by Petrini [61]. 
Likewise, the combined effect of recruitment and de-recruitment was studied in a model 
with 27k parallel alveolar units which shed light on the pressure-volume relationship of 
these alveolar compartments [62]. The effects of ventilation-perfusion inequality on the 
lung, gas exchange and pulmonary ventilation were analysed using a model by JB West 
[63]. Moreover, this study also examined the efficiency of the model under a different 
number of alveolar compartments and proposed that, in a multi compartmental model, 
a minimum of 100 compartments are essential to provide the optimal trade-off between 
accuracy and computational complexity. However, this model does not take into 
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consideration the individual alveolar compliances, inflow resistances and vascular 
resistances. 
In another work by Dickinson [64], a model called “MacPuf” was developed. This 
cardiorespiratory simulator takes into account the ventilation control, pulmonary 
circulation, gas exchange and tissue metabolism. Each stage of modelling has been 
carefully designed, considering critical aspects like dissociation curves for O2 and CO2, 
shunt, dead space etc. Furthermore, the model can represent mechanical ventilation 
with PEEP. 
On the other hand, there are many studies utilising single or two-compartmental 
models. These models offer less computational complexity while providing better 
insight into poorly understood physiological behaviour. In a study, Swanson and 
colleagues [65] propose a two-compartmental model to investigate alveolar gas exchange 
under exercise. Other examples of studies using single/two-compartmental models of 
the respiratory system include Hotchkiss et al. [66], Vidal Melo et al. [67, 68], Joyce et al. 
[69], Farmery et al. [70] and Liu et al. [71]. Yet, single/two-compartmental respiratory 
models do not deliver enough accuracy for simulating lung injury under pathological 
conditions and modelling treatments. They are also incompetent when it comes to 
representing ventilation/perfusion distribution, tidal breathing, series or parallel 
resistances etc. 
“VentSim” is a respiratory model introduced by Rutledge [72], which is an expanded 
version of his previous work “VenPlan” [18]. The three chief model components, 
comprising ventilator component, an airway component and a circulation component, 
have been wisely embedded into the model by dint of linked first-order differential 
equations. Yet, the simulator has not been validated with actual ventilated patients’ data. 
“VO2.htm” is an interactive computer simulation of pulmonary gas exchange by 
Kapitan [73] that is web based and indicates the final effect on the arterial blood gas 
composition caused by simultaneous change in multiple factors. For more details on the 




2.4. A high-fidelity computational simulator of integrated 
cardiorespiratory pathophysiology 
The simulator used as the basis for the studies described in this thesis is a multi-
compartmental computational model that uses an iterative technique to simulate 
integrated respiratory and cardiovascular pathophysiological scenarios. The simulator 
has been developed over the past several years and has been applied and validated on a 
number of previous studies [76–84]. 
In contrast to previous models of pulmonary pathophysiology that included only two or 
three alveolar compartments, this model allows the user to define up to several hundred 
individual compartments (each with its own individual mechanical characteristics) to be 
implemented in the simulation. An alveolar compartment in the model represents a 
cluster of alveoli in the lungs (different lung segments) rather than one alveolus, so that 
the total number of compartments comprises the whole lung. Each of these alveolar 
compartments has a unique and configurable bronchiolar resistance, pulmonary vascular 
resistance, stiffness index, and extrinsic pressure. The ability to adjust these parameters 
individually across all alveolar compartments allows the model to recreate the 
heterogeneous effects of disease, e.g. COPD, on the overall physiology of the lung. 
The model also includes specific equations to represent the effects of alveolar collapse, 
threshold opening pressure, alveolar stiffening, and airway obstruction. The net effect of 
these components of the simulation is that defining, clinical features of acute lung injury 
may be observed in the model, e.g. alveolar gas trapping, collapse-reopening of alveoli, 
pulmonary oedema, etc. However, the model does not currently consider the spatial 
arrangement of different lung regions (i.e. from the top to the bottom of the lung) and 
its effect on V/Q mismatch. 
Moreover, the model includes representations of multiple interacting organ systems 
(cardio-pulmonary-vascular) and incorporates an unprecedented level of physiological 
detail including multiple alveolar compartments, multi-compartmental gas-exchange, 
viscoelastic compliance behaviour, interdependent blood-gas solubility and haemoglobin 
behaviour and heterogeneous distributions of pulmonary ventilation and perfusion. 
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Each model component is described as several mass conserving functions and solved as 
algebraic equations, obtained or approximated from the published literature, 
experimental data and clinical observations. These equations are solved in series in an 
iterative manner, so that solving one equation at the current time instant determines the 
values of the independent variables in the next equation. At the end of the iteration, the 
results of the solution of the final equations determine the independent variables of the 
first equation for the next iteration. 
The pulmonary model consists of the mechanical ventilation equipment, anatomical and 
alveolar dead space, anatomical and alveolar shunts, ventilated alveolar compartments 
and corresponding perfused capillary compartments. The model simulates all relevant 
aspects of pulmonary dynamics and gas exchange such as the transport of air from 
mouth to airway and alveoli, the gas exchange between alveoli and their corresponding 
capillaries, and the gas exchange between blood and peripheral tissue compartment. The 
pressure differential created by the mechanical ventilator drives the flow of gas through 
the system. The model includes series dead space to represent the trachea, bronchi and 
the bronchioles. The volume of dead space is split into 50 stacked layers of equal 
volumes.  No mixing between the compartments of the series dead space is assumed. 
The lung model incorporates up to several hundred independently configurable alveolar 
compartments, implemented in parallel, allow the model to accurately simulate alveolar 
shunt and alveolar dead space. 
Figure 1 shows a simplified, diagrammatic representation of the model. The inhaled air 
is initially assumed to consist of five gases: oxygen, nitrogen, carbon dioxide, water 
vapour and a 5th gas (α) used to model additives. The atmospheric pressure is fixed at 
101.3kPa and body temperature is fixed at 37.2°C. During an iteration of the model, the 
flow (𝑓) of air to or from 𝑖th alveolar compartment is determined by the following 
equation: 
𝑓𝑖 =
( Pv −  P𝑖)
(Ru + RA, 𝑖)
               for 𝑖 = 1, … , NA (1) 
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where  Pv and  P𝑖 are the pressure supplied by the mechanical ventilator and the pressure 
in the 𝑖th alveolar compartment respectively. Ru represents the constant upper airway 
resistance and RA, 𝑖 is the bronchial inlet resistances of the alveolar compartment 𝑖. NA 
is the total number of alveolar compartments (for the studies in this thesis, NA=100). 
The rationale for choosing 100 compartments in this case is based on both a study on 
COPD patients employing the same simulator which found 100 alveolar compartments 
as the optimal trade-off between model accuracy and complexity, and another study in 
the literature which evaluated the efficiency of a multi compartmental model under a 
different number of alveolar compartments [63].  
The total flow of air entering the series dead space is the sum of all flows to/from the 
alveoli. The volume of gas “𝑥” in the 𝑖th alveolar compartment (v𝑖,𝑥), is updated as 
follows: 
v𝑖,𝑥 =  {
v𝑖,𝑥 − 𝑓𝑖 ∙
v𝑖,𝑥
v𝑖
               Exhaling
v𝑖,𝑥 + 𝑓𝑖  ∙ FNSD             Inhaling 
 (2) 
where 𝑥 is any of the five gases and v𝑖 is the total volume of the 𝑖
th alveolar 
compartment (sum of the volume of the five gases in the compartment.) FNDS is the 
fraction of gas in the last layer of the dead space. 
Hypoxic Pulmonary Vasoconstriction (HPV) is the intrinsic reaction of the respiratory 
system to low levels of oxygen in blood. This mechanism restricts the blood flow in the 
pulmonary blood vessels where there is not enough oxygen. This is modelled as a simple 
function, resembling the stimulus response curve suggested by [85], and is incorporated 
into the simulator to gradually constrict the blood vessels as a response to low alveolar 















To model the equilibration process between the alveolar compartment and the 
corresponding capillary compartment, small volumes of each gas (O2 and CO2) is 
moved between the compartments until there are identical partial pressures of these 
gases in both compartments (i.e. they differ by <1%). In blood, the total O2 content 
(CO2) is carried in two forms, as a solution and as oxyhaemoglobin (saturated 
haemoglobin): 
CO2 = SO2 ∙ Huf ∙ Hb + PO2 ∙ O2sol (3) 
In this equation, SO2 is the haemoglobin saturation, Huf is the Hufner constant, Hb is 
the haemoglobin content and O2sol is the O2 solubility constant. In order to describe 
the O2 dissociation curve, the following pressure-saturation relation is used in the 
model, as proposed in [45]: 
SO2  = (((PO2
3 + 150 ∙ PO2 )
−1
× 23400) + 1)
−1
 (4) 
PO2 is the partial pressure of oxygen in the blood. In view of the appropriate correction 
factors in base excess (BE), temperature (T) and pH [44], PO2 is calculated as: 
PO2 = 7.5006168 ∙ PO2 ∙ 10
[0.48(pH−7.4)−0.024(T−37)−0.0013∙BE] (5) 
pH is the blood pH level and the constant ‘7.5005168’ is the pressure conversion factor 
from kPa to torr. 
Using the Henderson-Hasselbach logarithmic equation, the plasma CO2 content can be 
calculated (Eq.6). Next, the CO2 content of the blood (CCO2) is deduced from Eq.7, [41]. 
CCO2plasma = 2.226 ∙ CO2sol  ∙  PCO2 ∙ (1 +  10
(pH−pK′)) (6) 
CCO2 = CCO2plasma  ∙  [1 −
0.0289 ∙ Hb




where CO2sol is the plasma CO2 solubility coefficient, pK' is the apparent pK, PCO2 is 
the partial pressure of CO2 in plasma, and ‘2.226’ is the conversion factor from 
miliMoles·L-1 to mL·100mL-1. Values for CO2sol and pK' can be deduced from, [86]: 
CO2sol = 0.0307 + 0.0057 ∙ (37 − T) + 0.00002 ∙  (37 − T)
2 (8) 
pK′ = 6.086 + 0.042(7.4 − pH) + (38 − T) (0.00472 + (0.00139 −  (7.4 − pH))) (9) 
PCO2 is consequently determined by incorporating the standard Henry’s law and 
CO2sol. For pH, the Henderson-Hasselbach and the Van Slyke equations [87] are 
combined, resulting in the following equation: 




and bicarbonate concentration (HCO3) can then be calculated by, [87]: 
HCO3 = ((2.3 × Hb + 7.7) × (pH − 7.4)) +
BE
(1 − 0.023 × Hb)
+  24.4 (11) 
In order to update the arterial blood gas “x” content, the non-shunted blood from 
pulmonary capillaries (Ccap,x) as well as the anatomical shunt (Sh) are mixed with arterial 
blood using the equation below: 
Ca,x =
CO ∙ (Sh ∙ Cv,x + (1 − Sh) ∙ Ccap,x) + Ca,x ∙ (va − CO)
va
 (12) 
In the above, CO is cardiac output and va is the arterial volume. The shunt fraction 
(QS/QT) in the model is calculated as: 




In the simulator, the peripheral tissue is incorporated as a single compartment. Similar 
to alveolar equilibration, the peripheral capillary and tissue equilibrium is modelled by 
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removing the consumed O2 (VO2) from blood and adding the produced CO2 (VCO2). 
Metabolic production of acids, other than carbonic acid via CO2 production, is not 
modelled. After peripheral tissue equilibration of gases, the venous calculations of 
partial pressures, concentrations and pH calculations are performed using comparable 
equations to those above. 






where the end-inspiratory lung volume (Vmax), end-expiratory lung volume (Vmin), 
maximum pressure in lung (Pmax) and the minimum pressure in lung (Pmin) are 
obtained directly from the model at the end of every breath. The simulated patient is 
assumed to be under complete mechanical ventilation. Consequently, the effects of 
ventilatory autoregulation by the patient are not currently incorporated into the models. 
For the 𝑖th alveolar compartment, the pressure of the compartment (P𝑖) is determined 
by: 
P𝑖 = S𝑖(V𝑖 − Vc)











V𝑖 is the given volume of alveolar compartment in millilitres. Vc is defined as a 
“collapsing volume” at which the alveolus tends to empty. The parameter Pext is an 
extrinsic pressure which is representative of the net pressure generated outside each 
alveolus, such as the outward pull of the chest wall (positive component indicating 
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distend) and the compressive effect of interstitial fluid in the alveolar wall (a negative 
component indicates compression from outside the alveolus tending to cause collapse). 
S𝑖 is a scalar that determines the alveolar compliance. A higher S𝑖 suggests a stiffer 
compartmental behaviour, which requires a larger pressure from the mechanical 
ventilator to drive air into the compartment. The unit of S𝑖 is “cmH2O mL-2”. All of the 
abovementioned parameters (Pext,𝑖, S𝑖 and Vc) are different yet essential components for 
representing a diseased lung. 
The alveolar compartments in the model are placed in a parallel arrangement and 
interact with the series dead space with respect to the movement of gases. The total 














where RB,𝑖 is the bronchial inlet resistance of the 𝑖
th compartment given as: 
RB,𝑖 = m𝑖 ∙ RB0 (19) 
and RB0 corresponds to the default bronchial inlet resistance of an alveolar 
compartment. RB0 is set to 10-5·NA kpa ml-1 min-1 (6 cmH2O L-1 s-1) for adults; the inlet 
resistance is higher for a model with more compartments as the volume of each 
compartment decreases; giving, for example, a resistance of 0.001 kpa ml-1 min-1 in each 
compartment for 100 compartments. m𝑖 is a coefficient representing a dynamic change 
in airway resistance and is determined by the following equation: 
m𝑖 = {
1                   Ptrachea ≥ TOP𝑖
105              Ptrachea < TOP𝑖
 (20) 
where Ptrachea is the pressure in the trachea and TOP𝑖  is defined as the threshold 
opening pressure of the 𝑖th alveolar compartment with a value between 5 and 60 
cmH2O [88]. TOP𝑖  indicates a pressure that a collapsed alveolar unit must attain to 
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reopen. Moreover, in order to model recruitment as a time dependant process where 
different airways recruit at different times, the condition Ptrachea ≥ TOP𝑖 has to stay 
satisfied for a specific period of time (τc,𝑖) for a compartment to be recruited. 
Otherwise, m𝑖 is set to 105 again. 













where the resistance for each compartment RV,𝑖 is defined as: 
RV,𝑖 = δV𝑖RV0 (22) 
RV0 is the default vascular resistance for the compartment with a value of 160·NA 
dynes s cm-5 min-1 for adults, and δV𝑖 is a coefficient that can be used in order to modify 
the vascular resistance. 
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Chapter 3:  
 
 
Investigating different administration 
mechanisms for a novel compound to lower 
pulmonary hypertension in COPD 
3.1. Summary 
In this chapter, a highly fidelity computational simulator of pulmonary physiology is 
employed to evaluate the impact of a soluble guanylate cyclase (sGC) modulator on gas 
exchange in patients with chronic obstructive pulmonary disease (COPD) and 
pulmonary hypertension (PH) as a complication. Three virtual COPD patients were 
configured in the simulator based on clinical data. In agreement with previous clinical 
studies, modelling systemic application of a sGC modulator results in reduced partial 
pressure of oxygen (PaO2) and increased partial pressure of carbon dioxide (PaCO2) in 
arterial blood, if a drug-induced reduction of pulmonary vascular resistance (PVR) equal 
to that observed experimentally is assumed. In contrast, for administration via dry 
powder inhalation (DPI), the performed simulations suggest that the treatment results 
in no deterioration in oxygenation. For patients under exercise, DPI administration 




Chronic obstructive pulmonary disease is one of the leading causes of morbidity and 
mortality in most countries [89, 90]. The World Health Organization (WHO) estimates 
that COPD was the fifth leading cause of death in high-income countries in 2002, and it 
was the sixth leading cause of death in nations of low and middle income [91]. 
Moreover, according to WHO, COPD is predicted to become the third leading cause of 
death in 2030 [92]. COPD has been identified as a major global health burden based on 
its high prevalence and significant health-care costs [93, 94]. 
A serious complication of COPD is pulmonary hypertension (PH), a progressive and 
debilitating condition associated with a sustained increase in mean pulmonary artery 
pressure (mPAP) that results from excessive vasoconstriction and remodelling of the 
pulmonary arteries [95]. It is associated with shorter survival and has been seen as a 
predictive factor for worse clinical outcomes and frequent use of health resources [96, 
97].  Accordingly, there has been significant interest in exploring PH-specific therapies 
in patients with COPD. Various vasodilating drugs with different modes of action have 
been investigated in clinical studies [98]. Most of these studies considered systemic 
applications (oral administration), although some also considered administration via 
inhalation. Generally, these studies aimed for a dilation or relaxation of the pulmonary 
arterial vessels, thus lowering pulmonary vascular resistance. On the other hand, 
unselective vasodilation of pulmonary vessels may also lead to a relief of hypoxic 
vasoconstriction in low-/non-ventilating areas of the lung, and consequently to 
increased ventilation-perfusion (V/Q) mismatch and a deterioration of oxygenation. 
One of the most extensively investigated drugs in COPD-PH is the phosphodiesterase-
5 (PDE-5) inhibitor Sildenafil (Pfizer) [99–104]. When given systemically, i.e. oral or 
intravenous administration, in acute studies Sildenafil (Pfizer) consistently resulted in a 
reduction of mPAP and an improvement of exercise capacity and six-minute walking 
distance [101, 102, 104]. While during exercise there seems to be no adverse reaction, at 
rest the hemodynamic changes occurred at the expense of worsening gas exchange due 
to increased V/Q mismatching [101]. In chronic studies no clear positive effect of the 
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treatment with Sildenafil (Pfizer) as compared to placebo could be observed, with 
positive [100] as well as negative outcomes being reported [99, 103]. 
Trials have also been undertaken with Bosentan (Actelion), an oral endothelin receptor 
antagonist, in treating PH in COPD. Stolz et al. found in severe COPD patients that 
those treated with Bosentan (Actelion) suffered from a decreased quality of life, 
worsening arterial oxygen saturation and an increased alveolar-arterial gradient with no 
change in exercise capacity [105]. In another study the treatment group benefited from 
significant improvements in mPAP, pulmonary vascular resistance (PVR) and six-min 
walk distance without a significant decline in oxygenation [106]. 
Inhalation therapy was investigated in COPD-PH patients with inhaled nitric oxide 
(iNO) [107–114] and the prostacyclin analogue Iloprost (Schering/Bayer)[115–117]. 
The trials with iNO consistently demonstrated a considerable and concentration 
dependent reduction of PVR [107, 109–114]. The response of gas exchange, in 
particular of oxygenation, to iNO therapy is however heterogeneous. Though, clear 
concentration dependence cannot be derived from the different studies, there is at least 
evidence that at lower iNO concentrations arterial oxygenation is improved or remains 
unchanged with iNO inhalation [107, 109, 111, 114], while at higher concentrations 
(>20 ppm) there is no gain in oxygenation [110] or even a deterioration [112, 113]. The 
latter response is presumably the result of increased V/Q mismatch caused by nitric 
oxide releasing hypoxic vasoconstriction in poorly ventilated regions of the lung. 
However, the opposite effect was also observed in another study, where an 
improvement of PaO2 was recorded with high nitric oxide concentrations [114]. 
An inconsistent picture also emerges from the studies with inhaled Iloprost 
(Schering/Bayer). While Boeck and colleagues did not find positive effects but instead a 
worsening of gas exchange for two different Iloprost (Schering/Bayer) doses in a cross-
over study [115], two other studies reported improvements in V/Q matching, gas 
exchange and exercise tolerance [116, 117]. 
Recently Riociguat (Bayer), a stimulator of soluble guanylate synthase (sGC) has been 
approved for treatment of pulmonary arterial hypertension and chronic 
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thromboembolic PH after it showed improved six-minute walk distance, compared with 
placebo, and also improved PVR, functional class, dyspnoea, and health-related quality 
of life in these diseases [118, 119]. Riociguat (Bayer) was also investigated in a single 
dose study with COPD patients with borderline or manifest PH (mPAP >= 23 mmHg) 
[120]. Similar as for other therapies, significant reductions of mPAP and PVR could be 
demonstrated in this patient population. Although some reduction in oxygenation 
occurred with orally administered Riociguat (Bayer) in these studies, this was not at 
levels which were judged to be clinically relevant. 
Overall, the results from the different studies discussed above indicate that: 
• The pharmacological principle of vasodilation is generally appropriate for 
improving pulmonary hemodynamic and exercise tolerance of COPD-PH 
patients 
• Systemic administration of drugs bears a high risk of deterioration of V/Q 
mismatch due to relief of hypoxic vasoconstriction  
• Inhaled administration shows positive effects and may, in contrast to systemic 
administration, lead to improved V/Q mismatching, although also the opposite 
can happen if the distribution of the drug is not strictly limited to well ventilated 
regions of the lung, or if alveolar absorption is high and considerable systemic 
exposure occurs after inhalation. 
One potential limitation to consider is the fact that inhalation with a metered dose or 
dry powder inhaler, typically used in lung diseases such as COPD and asthma [121, 122], 
is associated with a deep breath. This could, however, deteriorate the advantage of 
inhaled administration, as a deep breath may result in drug particles being deposited in 
lung areas that are not ventilated at rest.  
The complexity of the findings summarized above highlights the fact that the role of 
different therapies and corresponding administration methods in COPD related PH 
needs further exploration. In this study, simulation approaches employing a high-fidelity 
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simulation model were adopted to evaluate the effects of a vasodilator, in terms of 
hemodynamic and oxygenation, in COPD patients with PH.  
In the following, the ability of the simulation model to recapitulate observed changes in 
gas exchange after systemic administration of the sGC stimulator Riociguat (Bayer) is 
demonstrated, based on the experimentally determined reductions of pulmonary 
vascular resistance. Thus validated, the model is then used to evaluate the effects of 
alternative administration methods (dry powder inhalation via a deep breath and 
inhalation via normal breathing e.g. using a ventilator) of the drug. Also, the 
consequences of administering the drug to patients while under exercise is quantitatively 
investigated. 
3.3. Materials and Methods 
3.3.1. Model matching to patient data 
Over the past years, Genetic Algorithms (GA) has been widely used as a robust search 
and optimisation approach. The method is effective for problems with both large and 
small parameter search spaces. Lately, many studies have also employed GA in a range 
of different problems in physiological modelling [123, 124]. Inspired by the evolutionary 
process concepts observed in nature such as selection, mutation, recombination etc., 
this technique produces a set of fittest candidates from the initial population. The 
randomly sourced initial population of candidates undergoes a repetitive evolutionary 
process of reproduction through selection for mating according to a fitness function, 
and recombination via crossover with mutation. A complete repetitive sequence of 
these genetic operations is called a generation. The performance of each candidate is 
evaluated by means of a fitness function defined from the knowledge domain and 
specific to the problem.  
Global optimisation methods such as GA are more likely to converge to a global 
optimal because of their stochastic nature. However, this improved performance comes 
with the price of higher computation time compared with local methods. The reader is 
referred to [125] for more details of different operators, binary coding schemes and the 
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theory of genetic search. Many different termination criteria can be used to stop the 
process of GA seeking for the best fit. In the current study, an adaptive termination 
criterion is used where the GA terminates the search when there is no improvement on 
the best solution achieved over a specified number of successive generations. 
To speed up the optimization process, a parallelised computer code implementation of a 
genetic algorithm was employed in this study. The cost function evaluation process 
associated with a population can be accelerated hugely by distributing the tasks to 
multiprocessors (multiple cores and/or multiple machines). Optimization of the model 
to patient data was performed using the “Tinis” high performance computing cluster 
provided by the University of Warwick (3488 x Intel Xeon E5-2630 v3 2.4 GHz 
Haswell cores; 16 cores per node; 203 nodes; 64 GB DDR4 memory per node / 4 GB 
per core) running Matlab (2017b) and utilizing the global optimization and parallel 
computing toolboxes. An adaptive termination strategy, which allows the optimization 
algorithm to run as long as necessary, was applied for each case to ensure the global 
optimal was reached.  
For the present work the pulmonary simulator is matched to the characteristics of three 
COPD-PH patients with differing gas exchange properties which were included in the 
previous study with Riociguat (Bayer) [120]. The respective data on PaO2, PaCO2, dead 
space fraction and V/Q at baseline (see Table 1) were taken from the study report. The 
optimization problem is formulated to find the configuration of model parameters that 










Y = [PaO2, PaCO2, DSV, VQ1, VQ2] (24) 
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where Y is the vector of data values and Ŷ is the vector of model estimated values for 
arterial partial pressures of oxygen and carbon dioxide (PaO2 and PaCO2 respectively), 
dead space to ventilation fraction (DSV), 0.001<V/Q<0.1 (VQ1) and 0.1<V/Q<10 
(VQ2). The best set of model parameters which gives the minimum value for J is 
selected as the best match. In case of multiple solutions with similar cost, no difference 
in the performance of different solutions were observed. 
The three example data sets where chosen in order to cover a wide spectrum of COPD 
pathophysiology. For two of the patients, multiple inert gas elimination technique 
(MIGET) was applied in order to determine data on V/Q mismatch, and thus for these 
patients a comparison of data and model outputs on V/Q is also presented. The PVR 
of individual patients were set based on the provided individual data. As there was no 
available data indicating if the patients suffered from alveolar loss or not, this was not 
modelled. Also, the overall high airway resistance of COPD patients is taken into 
account by means of modelling the obstructed airways (i.e. airways with very high 
resistance values). 
Table 1 reports the matching results for all three COPD patients considered. From the 
table, it is clear that the models are closely matched to the data with percentage errors 
below or around 1%. In order to assess the robustness of subsequent findings, 100 
random parameter sets within ±5% of the best fit for each patient were also generated. 
All the analyses described below were applied to the best-fit model, and findings were 
subsequently checked for consistency on all 100 parameter sets around each optimal 
patient parameter set. 
3.3.2. Modelling of drug effects and application methods 
The change from baseline of PVR after drug administration was used as an input for the 
model. In order to specifically simulate the behaviour of Riociguat, the respective mean 
relative PVR curve as measured for a dose of 2.5 mg Riociguat (Bayer) [120] was 
considered for the present simulations (see Figure 2). Individual data on PVR changes 
after treatment with Riociguat (Bayer) were not published in [120] and therefore the 






Table 1. Patient matching results 
 Patient 1 Patient 2 Patient 3 
 data model data model data model 
PaO2 (mmHg) 129.2 129.3 76.8 76.69 66.0 65.5 
PaCO2 (mmHg) 44.1 44.12 49.8 49.85 32.5 32.3 
Dead space (%) 45.8 45.8 39.9 39.8 - 40.0 
0.001<V/Q<0.1 (%) 33.1 33.2 13.6 13.61 - 22.4 





Figure 2. Mean change of PVR from baseline over time in patients receiving a single dose of 
Riociguat 2.5mg [120]. 
 















In the simulator, the pulmonary vessels are modelled as a parallel network with 100 
compartments. Each compartment has a vascular resistance denoted as PVR𝑖 and the 












Reduction of PVR is thus captured by changing the resistances of individual 
compartments due to drug administration. For a given temporal profile of the drug 
induced change of PVR (see Figure 2) the temporal changes of PVR𝑖 in the individual 
compartments are calculated as follows. 
After systemic application the drug substance is delivered to the lung through the blood 
circulation. The assumption in this case is that the drug will act equally on all 
compartments with blood going through them, and produce the same amount of 
vascular resistance reduction: 
PVRi̅̅ ̅̅ ̅̅ ̅(t) = PVR𝑖
baseline − α(t) ∙ ΔPVR (26) 
Where ΔPVR is a fixed value denoting the equal reduction in resistance for all 
compartments, and 𝛼(t) is a time dependent variable reflecting the variability of the drug 
effects over time. Combining Eqs. 25 and 26, the desired PVR reduction shown in 
Figure 2 can be straightforwardly implemented by adjusting 𝛼. 
In the case of inhaled application of an aerosol, for example, containing the drug, it is 
assumed that deposition of the drug in different compartments of the lung is 
proportional to the extent of ventilation in these compartments. This means that the 
drug only reaches compartments of the lung which are ventilated under normal 
breathing conditions. Also, it is assumed that an inhaled application will not lead to 
systemic exposure causing any systemic effect, nor any effect in the parts of the lung not 
directly addressed via inhalation. 
Despite the assumption that the drug reaches only ventilated areas, and thus only in a 
part of the lung will a vasodilatory effect be induced, a similar reduction of total PVR is 
Chapter 3 
 29 
assumed to be achievable as observed with the systemic application (Figure 2). This 
assumption is supported by the fact that for inhaled iNO, PVR reductions in the range 
of 25-30% were observed [109, 110, 114]. Yet, as there is no data on the inhaled 
reduction level of PVR with Riociguat, the possibility that the inhaled effect may overall 
be lower when given systemically cannot be ruled out. Furthermore, it is assumed that 
the inhalation process is short, compared to the absorption and induction effect and 
thus the time course of the PVR reduction would be the same as the one observed after 
oral administration (Figure 2). Furthermore, it is assumed that the drug effect is 
proportional to the amount of drug deposited. Accordingly, the changes in vascular 
resistance due to treatment with the drug for each compartment is proportional to the 
ventilation reaching that compartment, and consequently the changed resistance PVRi̅̅ ̅̅ ̅̅ ̅ is 
given by: 
PVRi̅̅ ̅̅ ̅̅ ̅(t) = PVR𝑖




, β(t) reflects the temporal effect of the drug, VTalv(𝑖) is the 
ventilation of alveolar compartment 𝑖 and VT is the total tidal volume. Combining 
Eqs.25 and 27, the desired PVR reduction in Figure 2 can be implemented 
straightforwardly by adjusting β. 
Independent of the application device, dry powder inhalation always needs a deep 
breath for inhaling the drug dose. Deep inhalation (DI) causes a rapid increase of lung 
volume which results in dilating of the airway and a temporary reduction of airway 
resistance [126, 127], which will affect how the drug is delivered. The effect of this 
reduction of airway resistance is modelled, with the underlying assumption that 
compartments with larger initial volumes will exhibit smaller reductions in airway 














the new airway resistance for compartment 𝑖 is then given by: 






Where Voli is the volume of compartment i, and Xaw is a scaling parameter related to 
tidal volume. It can be seen that a smaller Voli will lead to a bigger reduction of airway 
resistance. For example, setting Xaw = 20, then: i) if Voli = 20ml, ∆awi = 0.5, ii) if Voli = 
80ml, ∆awi = 0.8. DI is replicated in the virtual patients by applying a threefold increase 
in tidal volume for a period of five respiratory cycles. 
In COPD patients, oxygen consumption is more restrained by impaired pulmonary 
ventilation than by oxygen delivery, which imposes exercise limitations upon these 
patients. Under exercise, VO2 for COPD patients has been shown to increase to 0.7 
L.min-1 (SD=0.25) on average [128, 129]. In response to the elevated VO2, minute 
ventilation and cardiac output rise accordingly to deliver more oxygen to the tissues 
[129, 130]. In our model, the physiological effects of initiating exercise were simulated 
by progressively increasing VO2 every minute to 0.35, 0.5, 0.6, 0.65 and 0.7 L.min-1 in 
the virtual patients. Minute ventilation was subsequently increased as required to 
maintain the arterial blood gases (ABG) at their pre-exercise values, using the 
exponential relation between tidal volume and respiratory rate (RR) in [131]. Cardiac 
output was raised to 8.2 L.min-1 according to the average change observed in [129], and 
following the increase in CO an additional 10% reduction in PVR to that caused by the 
drug was applied [132]. Exercise was simulated to start 30 minutes after administration 
of the drug by inhalation with deep breath and continues for 90 minutes. The at-rest 
and under-exercise values for tidal volume and respiratory rate as well as the 









Figure 3. Values for tidal volume and respiratory rate as well as the corresponding changes to 
PaO2 and PaCO2 at-rest and under-exercise. 
Minute ventilation was subsequently increased as required to maintain the arterial blood gases 
(ABG) at their pre-exercise values, using the exponential relation between tidal volume and 



































































3.4.1. Systemic application 
The average PVR reduction profile observed with 2.5 mg Riociguat (Bayer) was applied 
to the three configured virtual COPD patients, for each of the three application 
methods (systemic, inhaled and DPI). The changes in gas exchange parameters, PaO2 
and PaCO2 over time were then recorded, and are shown for each patient in Figure 4 
(A) and (B). In the case of systemic application, reductions in PaO2 and increases in 
PaCO2 were observed for all 3 patients. For systemic application, the average percentage 
change for PaO2 is -24.1% and for PaCO2 is +9.2%, which are consistent with results 
reported in a previous clinical study with Riociguat (Bayer) [120]. 
3.4.2. Inhaled application 
In contrast to the systemic application, an inhaled administration leads to considerable 
improvements in oxygenation, as shown in Figure 4 (G) and (H). The maximum 
increases of PaO2 are 11%, 4% and 4% with an average of 6.33%, while the maximum 
decreases of PaCO2 are -11%, -6% and -5%, respectively, with an average of -7.33%. 
This is as expected, since in this case no deep breaths are required on the part of the 
patients and thus the entire compound is delivered only to the normally ventilated 
regions of the lung. 
3.4.3. Dry powder inhaler application at rest and under exercise 
Figure 4 (C) and (D) shows the effects of application of the same compound using dry 
powder inhalation via a deep breath at rest, which is a more realistic scenario for an 
inhaled therapy in COPD. With the same PVR reduction profile, changes of blood gas 
values are in between those calculated for the systemic and continuous inhaled 
applications. In fact, it can be seen that PaO2 is slightly increased and PaCO2 is slightly 
reduced for all 3 patients. The maximum increases of PaO2 are 2%, 1% and 1% with an 
average of 1.33%. The maximum decreases of PaCO2 are -2%, -1% and -1%, 
respectively, with an average of -1.33%. Figure 4 (E) and (F) show that undertaking 
exercise for one hour after application by DPI produces further improvements in 
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oxygenation, with maximum increases of PaO2 of 5.1%, 0.8% and 2.5% with an average 
of 2.8%, and maximum decreases of PaCO2 of -2%, -3.3% and -2.5%, respectively, with 
an average of -2.6%. 
3.4.4. Robustness analysis 
To test the robustness of our results, for each patient, all simulations (i.e. systemic 
application, inhalation with deep breath at rest and under exercise and inhalation with 
normal breath) were repeated on 100 parameter sets randomly chosen within bounds of 
±5% of the optimal parameter set found by means of global optimization. Figure 5 
compares the maximum change in PaO2 and PaCO2 observed for each patient and each 
application method using the optimal parameter set (squares) with the average 
maximum change in PaO2 and PaCO2 calculated using 100 random parameter sets 
(circles with one standard deviation (SD) as error bars). The outcomes confirm the 
consistency of the observed responses to the different methods of drug administrations, 
i.e. the average maximum change from baseline for PaO2 and PaCO2 across all random 
sets for each patient closely matches the maximum changes reported when employing 
the optimal parameter set during our previous analysis. Figure 6 to Figure 8 show time-







Figure 4. Simulation results for patients using different drug administration methods. 
The systemic administration deteriorates oxygenation while inhalation with normal breath 
improves oxygenation. Inhalation with deep breath had a minimal effect on oxygenation when 










Figure 5. Comparison of the maximum change in PaO2 and PaCO2 observed for each patient 
and each application method using the optimal parameter set (squares) with the average 
maximum change in PaO2 and PaCO2 calculated using 100 random parameter sets (circles with 
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Figure 6. Patient 1 - The Results of the simulations for 100 random parameter sets within ±5% 
of the best fit. 











Figure 7. Patient 2 - The Results of the simulations for 100 random parameter sets within ±5% 
of the best fit. 











Figure 8. Patient 3 - The Results of the simulations for 100 random parameter sets within ±5% 
of the best fit. 







This is the first study to investigate the efficacy of sGC modulators in COPD patients 
with PH by using computer simulation. The capability of the simulator to accurately 
describe the pathophysiological characteristics of gas exchange in COPD patients has 
already been demonstrated in a previous study [83]. That study showed that by including 
sufficient numbers of alveolar compartments in the model, accurate representations of 
both steady-state blood gases and ventilation-perfusion mismatch via V/Q curves could 
be obtained. In this study, close matching of the simulator to data on three patients 
whose hemodynamic was invasively monitored in the study reported by Ghofrani is 
further demonstrated [120]. Calculations of blood gas concentrations for these virtual 
patients, considering the observed temporal profile of average PVR changes after oral 
administration of Riociguat (Bayer), resulted in predictions of changes in O2 and CO2 
partial pressures that were consistent with those observed in the previous clinical study. 
These results can be considered as a validation of the capability of the pulmonary 
simulator to reliably describe the effects on gas exchange of compounds acting on the 
vascular resistance, in particular those stimulating sGC activity. 
As already discussed in previous publications, the systemic application of vasodilating 
drugs may lead to a worsening of V/Q mismatch and in consequence to an impairment 
of blood gas concentrations which limits their clinical use. This arises due to the non-
selective distribution of the drug to all parts of the lung, which together with inhibition 
of hypoxic pulmonary vasoconstriction leads to an excess of blood flowing to poorly 
ventilated parts of the lung.  
One potential way to avoid increases of V/Q mismatch is via inhaled administration, as 
long as the drug can be expected to only reach the ventilated parts of the lung. This 
avoids increasing the perfusion of non-ventilated lung compartments, provided systemic 
exposure stays low enough after inhalation not to be effective. Our results from 
simulations based on this scenario with inhalation of a hypothetical sGC modulating 
drug, which can be applied to act on the lung selectively, supports this hypothesis when 
it is administered by normal breathing. In contrast to the findings from systemic 
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administration, the inhaled application led to improved oxygenation, because perfusion 
of ventilated lung compartments was improved and effects on less well/non ventilated 
areas were limited. However, if the drug is formulated as a dry powder, its inhalation 
will usually be connected with a deep breath, which could cause a certain proportion of 
the compound to be deposited in regions of the lung that are not, or poorly, ventilated 
when returning to normal breathing at rest. To quantitatively investigate the trade-offs 
involved, the effect of inhaled administration of a compound inducing the same effect 
on total PVR as 2.5 mg oral Riociguat (Bayer) in COPD-PH with a deep breath is also 
modelled, causing the temporary recruitment of less well-ventilated areas. The resulting 
simulations reveal that although administering the drug by a deep breath may not 
improve oxygenation to the same extent as inhalation with normal breathing, it does 
avoid the potential deterioration in gas exchange associated with systemic drug 
administration. Moreover, when administered under exercise, most of the non/poorly 
ventilated parts of the lung in which the drug is deposited due to deep breathing 
become ventilated again as a result of increased minute ventilation, leading to further 
improvements in oxygenation. Interestingly, these findings are also in agreement with 
the results of a clinical trial on the systemic administration of the phosphodiesterase-5 
(PDE-5) inhibitor Sildenafil, which produced a worsening of gas exchange due to 
increased V/Q mismatching at rest, but not under exercise [101]. If lower effect on 
PVR is assumed during dry powder inhalation, the inhaled administration of the drug 
can still be more effective by trading off a lower effect on PVR with better preservation 
of V/Q matching in comparison to the systemic route of administration. 
A robustness analysis of these results performed by means of randomly selecting 100 
model parameter sets around the optimal values for each patient produced results that 
were uniformly consistent with the above findings. Our results highlight the potential 
advantages of administering sGC’s to patients via dry powder inhalation, rather than 
systemically, particularly when drug administration is combined with exercise. 
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Chapter 4:  
 
 
Evaluating strategies for lung-protective 
ventilation in paediatric acute respiratory 
distress syndrome using high-fidelity 
computational simulation  
4.1. Summary 
There have been no randomized trials to determine or evaluate lung-protective 
ventilation strategies in paediatric acute respiratory distress syndrome (PARDS), and the 
available observational studies are inconclusive. In this chapter, a new patient dataset is 
analysed to investigate whether, and how, more protective ventilation could be achieved 
in clinical practice. A novel high-fidelity computational simulator of PARDS was 
calibrated against individual patient data from an ongoing observational prospective 
cohort of PARDS from the Children’s Hospital of Philadelphia and used to investigate 
alternative strategies for achieving more protective ventilation without breaching safety 
limits on gas exchange. An initial cohort of 30 PARDS patients (age 3.1 ± 0.4 years 
ventilated via 5.0 mm internal diameter tracheal tubes under neuromuscular blockade) 
was selected for model and strategy development. Two additional cohorts were 
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subsequently selected to test the utility and generalisability of our results: 28 patients 
between 1 and 2 years of age, and 19 patients aged between 1 month and 18 years with 
tidal volumes >10 mL.kg-1. Interventions based on progressive reductions in tidal 
volume or driving pressure produced significant average reductions in multiple 
parameters associated with ventilator induced lung injury (tidal volumes, dynamic strain, 
mechanical power and driving pressure) in all three cohorts without compromising 
safety limits on gas exchange. Our results indicate that there may be general scope for 
implementing more protective ventilation in PARDS, suggest strategies for achieving 
this at the bedside, and demonstrate the utility of high-fidelity computational 
simulations in intensive care research. 
4.2. Introduction 
Mechanical ventilation in paediatric acute respiratory distress syndrome (PARDS) is less 
studied than in adults. After introducing the concept of ARDS in 1967 [133], neither the 
subsequent American-European Consensus Conference [134] nor the Berlin definition 
[135] considered differences between adult and paediatric patients when introducing 
definitions and guidelines. Consequently, current guidelines for mechanical ventilation 
in PARDS have largely been adapted from developments in the treatment of adult 
ARDS. In 2015, a paediatric-specific definition for PARDS was proposed by the 
Paediatric Acute Lung Injury Consensus Conference (PALICC) [136], which showed 
improved performance for PARDS, relative to adult ARDS definitions [137, 138]. 
However, recommendations for mechanical ventilation for children from both PALICC 
and the Paediatric Mechanical Ventilation Consensus Conference (PEMVECC)[139] 
largely rely on adult trials, with some contribution from paediatric observational data. 
Convincing evidence from clinical trials suggest that lower tidal volumes can reduce 
mortality in adult ARDS [4, 6, 140]. Recent research has highlighted the potential of 
other lung-protective strategies based on reducing driving pressure and MP to reduce 
ventilator induced lung injury (VILI) [141–144]. To date, there has been no randomized 
trial to determine the appropriate application of protective ventilation in PARDS. 
Observational studies are unclear, with conflicting results [145–148]. Concerns about 
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hypercapnia or increased ventilatory dead space in paediatrics may also contribute to the 
hesitancy to lower VT. There is therefore an urgent need for studies that can provide 
additional evidence regarding how lung-protective ventilation could be safely 
implemented during treatment of PARDS patients. It is hypothesized that analysis of a 
large-scale PARDS dataset using a computational simulator would allow us to (a) 
determine the scope (in terms of lowering VT, ∆P and MP) for safely implementing 
more protective ventilation, and (b) develop, test and directly compare alternative 
strategies for achieving this in practice. 
4.3. Materials and Methods 
4.3.1. Patient selection 
Development cohort  
Patients were selected from an ongoing (since 2011) observational prospective cohort 
[149] of intubated children meeting Berlin criteria for ARDS from the Children’s 
Hospital of Philadelphia (CHOP).  The study was reviewed by the CHOP Institutional 
Review Board, and requirement for informed consent was waived.  As the cohort was 
initiated prior to publication of the PALICC definition of PARDS [136], they were not 
screened based on oxygenation index; however, all patients met PALICC 
criteria.  Thirty subjects between 2.5 and 4 years of age ventilated via a 5.0 mm cuffed 
endotracheal tube during neuromuscular blockade were selected. The initial cohort is 
restricted to this age/size range to limit some of the variability during model 
development: e.g. subjects are selected with 5.0 mm internal diameter tracheal tubes, 
allowing consistency when calculating ventilatory resistance.  Furthermore, this age 
range was close to the median age (4 years) of the overall cohort.  Finally, paralyzed 
subjects are used to ensure reproducibility of the associations between ventilator 
changes and gas exchange, which would be confounded by spontaneous effort. Arterial 
blood gases and ventilator changes during the first 72 hours of PARDS were 
recorded.  The respiratory variables of peak inspiratory pressure (PIP), PEEP, and 
exhaled VT were collected at the ventilator for patients with VT ≥ 100 mL using 
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integrated software provided by the manufacturer (Dräger, Inc., Lübeck, Germany), and 
using a sensor proximate to the endotracheal tube for VT < 100 mL. Ventilator 
management and use of ancillary therapies were not protocolized. 
Test cohorts  
To test the utility and generalisability of the model and associated ventilation strategies, 
the analyses are repeated in a separate cohort of children aged 1 to 2 years.  This age 
group was selected because larger VT are commonly used to overcome perceived 
increases in dead space in younger lungs.  Finally, analyses were repeated in a cohort of 
19 children between 1 month and 18 years of age with VT > 10 mL.kg-1, as this is 
identified as a subgroup in which lung-protective strategies may have the greatest 
impact. The subjects in the test cohort 2 (high tidal volume) are not a subgroup of any 
other two cohorts. 
4.3.2. Simulator development and calibration to patient data 
The paediatric simulator was developed by performing a detailed revision of both the 
structure and parameters of the baseline simulator described in Chapter 2, Section 2.4, 
in light of the key differences between paediatric and adult physiology, as described 
below.   
There are a number of other respiratory physiology simulators for ARDS patients 
available in the literature [27, 64, 72–74, 150, 151], each of varying degrees of 
complexity and proven validity. Of these, only the model reported in [64, 74] can be 
applied to study paediatric patients. However, this model suffers from a number of 
significant limitations. These include the fact that (a) the model simulates the entire lung 
as a single compartment, (b) little justification/explanation is given for selection of 
model parameters, (c) the model specifies a lower age limit of 8 years, (d) the model 
cannot represent the pathophysiology of individual patients or disease states, and (e) no 
attempt has been made to validate its responses against real patient-data. To the authors’ 
knowledge, the results reported here represent the first application of a validated 
computational simulator to investigate novel ventilation strategies for PARDS. 
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There are a number of important differences between adult and paediatric pulmonary 
physiology. Some physiological features such as lung volume, cardiac output, oxygen 
consumption, airway resistance and pulmonary vascular resistance are highly variable in 
children depending on their age and weight. Thus, these different physiological 
parameters are required to be adaptively set in the model based on the age or weight of 
the target population. On the other hand, the stiffer lungs of paediatric subjects need to 
be taken into account when adjusting the volume-pressure equation of single alveolar 
compartments. The corresponding modifications applied to the model are fully 
described in this section. 
Cardiac output and the volume of functional residual capacity are estimated in the 
model using the following equations (The study population fro CO was composed of 
normotensive individuals 1 day to 85 years old and the study population for Vfrc 
included subjects aged 0.1-11.2 years old) [152, 153]: 
CO = 933 × weight(kg)
0.38          (ml. min−1) (30) 
Vfrc = 9.51 × weight(kg)
1.31                     (ml) (31) 
The total airway resistance and pulmonary vascular resistance are greater in children 
than in adults, decreasing as they grow older. The specific airway resistance can be 
estimated by [154]: 
sRtot = 1.3083378 − 0.00016486 ∗ age
3 − 0.03670306 ∗ sex            (kPa. s) (32) 
where sex is set to 1 for males and 0 for females (The equation was extracted from data 




                  (kPa. s. l−1) (33) 
and is distributed between the main airway and 100 parallel alveolar compartments in 
the model. Every alveolar compartment also has two resistances placed in series, namely 
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the alveolar inlet resistance and the upper bronchial resistance. The pulmonary vascular 




            (dyn. s. cm−5) (34) 
Note that the difference in values for mean pulmonary arterial pressure (MPAP) and 
mean pulmonary capillary wedge pressure (MPCWP) is virtually identical in children and 
adults. Hence, lower cardiac output plays the main role in generating higher PVR values 
for paediatric subjects. Furthermore, to characterize the stiffer nature of paediatric lungs 
at baseline the denominator of Eq.16 is reduced to 2000, 5000, 12000 and 50000 
cmH2O mL-2 for patients younger than 1, 1 to 2, 3 to 5 and 8 to 10 years old 
respectively. 
The simulator was matched to individual patient data using advanced global 
optimisation algorithms already described in Chapter 3 (see Section 3.3.1). The 
optimization problem is formulated to find the configuration of model parameters that 










Y = [PaO2, PaCO2, PE′CO2, PIP, mPaw, TOPmean, Vfrc] (36) 
where Y is the vector of data values and Ŷ is the vector of model estimated values. 
PE’CO2 is partial pressure of carbon dioxide at the end of an exhaled breath. The 
average threshold opening pressure of all the compartments (TOPmean) is optimized to 
be 20 cmH2O [88]. 
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4.3.3. Strategies for achieving lung-protective ventilation 
After matching the model to each individual patient, the potential for achieving lung-
protective ventilation in these patients was investigated by evaluating four different 
strategies on each of the virtual patients. The primary objective of the ventilation 
strategies was to progressively lower the risk of VILI without violating the following 
safety constraints:  
• PaO2 ≥ 8 (60) kPa (mmHg) 
• PaCO2 ≤ 8 (60) kPa (mmHg) 
• PIP ≤ 35 cmH2O 
• RR ≤ 40 bpm 
PaO2, PaCO2 and RR are partial pressure of oxygen in arterial blood, partial pressure of 
carbon dioxide in arterial blood and respiratory rate, respectively. These constraints are 
based on those used in clinical trials in adult ARDS, adapted to match the requirements 
of paediatrics [4, 156]. Also, the clinicians validated these ranges and the upper limits 
were observed in the current dataset. In cases where the data indicated that a patient’s 
initial settings did not comply with one or more of the aforementioned safety criteria, an 
attempt to reduce VILI was only made if it led to an improvement in the patient’s safety 
parameters (e.g. reducing PaCO2 or PIP). The four strategies were designed using 
volume control mode (VC-CMV) and based on physiological equations that are widely 
used in clinical practice, as follows: 
Strategy 1: VT was reduced in steps of 0.5 mL.kg-1 with each step lasting for 30 minutes. 
ABG and PIP were checked at the end of each phase until any further reduction 
violated one of the above constraints. RR was simultaneously adjusted at each step to 
maintain a constant minute ventilation (MinV) using: 
MinV = VT × RR (37) 
Strategy 2: Alveolar minute ventilation (MinValv) was kept constant instead of the general 
MinV. To do this, the amount of anatomical dead space (VD) must be taken into 
account, and thus MinValv was calculated from the equation [157–159]: 
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MinValv = (VT − VD) × RR (38) 
Strategy 3: Here, a strategy previously employed in [49, 160] was implemented in the 
simulator. In this approach, the MinValv was kept constant using Eq.38, and the 





where Finsp is the square inspiratory flow into the lung from the ventilator (no pause 
time used), and DC is duty cycle. As VT and RR had already been determined (same as 
strategy 2), Finsp could only be manipulated by varying DC in Eq.39. Thus, the difference 
between strategies 2 and 3 is that DC is set as constant for the former, while DC is 
adjusted to maintain a constant Finsp in the latter. 
Strategy 4: A recent study of adult ARDS [141] suggested that reductions in VT are most 
advantageous in terms of lowering mortality when this leads to a corresponding 
decrease in driving pressure (∆P), defined as the difference between plateau pressure 
(Pplat) and PEEP. 
∆P = Pplat − PEEP (40) 
Pplat is calculated directly from the simulator and represents the end inspiratory lung 
pressure. The employed strategy for decreasing ∆P works by increasing the applied 
PEEP and then adjusting VT to keep the plateau pressure constant. For this purpose, 
PEEP was increased by 1 cmH2O (causing a rise in Pplat) and then VT was reduced in 
steps of 0.5 mL kg-1 until Pplat returned to its initial value. The procedure was then 
repeated until one of the safety constraints was violated. 
4.3.4. Additional variables collected 
Strain, strain rate, and mechanical power were also calculated. Dynamic and static strain 
are markers of mechanical load during ventilation and can assist with understanding 
how the whole lung is affected by ventilation [161–163]. Although it is not possible to 
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measure exact values of strain in clinical practice, in the simulator they can be estimated 
as [161]: 








where VPEEP is the volume of gas in the lung due to PEEP and Vfrc(ZEEP) is the volume of 
functional residual capacity when PEEP is zero. Strain rate is strain divided by 





Mechanical power is calculated using the below equation [142]: 
MP = 0.098 × RR × {VT
2 × [0.5 × ELrs + RR ×
(1 + I: E)
60 × I: E
× Raw] + VT × PEEP} (44) 
where ELrs is the elastance of the respiratory system, I:E is the inspiratory-to-expiratory 
time ratio, and Raw is the airway resistance. The unit for MP is J min-1. 
4.3.5. Statistical analysis 
Data are presented as mean ± SD, or shown graphically using median, interquartile and 
total ranges. Data for all subjects, even those in whom VILI reductions could not be 
performed without violating safety constraints, is presented. To avoid violation of 
underlying distribution assumptions, variables were compared using nonparametric 
statistics when appropriate, including Spearman's rho, Wilcoxon signed-rank test, 
Mann–Whitney U test and Kruskal–Wallis H test. A two-sided p-value of < 0.05 was 




4.4.1. The simulator accurately represents individual patient data  
The ability of the simulator to accurately reproduce patient data was first verified by 
comparing its responses against data on the responses (PaO2 and PaCO2values) of 30 
patients (37% mild, 30% moderate, 33% severe per PALICC; 24% mild, 48% moderate, 
28% severe per Berlin) in the development cohort to mechanical ventilation. No strong 
correlation was observed between the reported values of VT (Kruskal-Wallis p = 0.7), 
PEEP (p = 0.4) and RR (p = 0.3) and PARDS severity category. Inspired oxygen 
fraction (FIO2) increased significantly with PARDS severity (Mann–Whitney p < 0.05). 
Average data across the cohort are shown in Table 2, while data for each individual 
patient are presented in Table 3 to Table 5. At baseline, 2 patients in the development 
cohort had VT > 10 mL.kg-1, 10 patients had VT 8–10 mL.kg-1, 16 had VT 6–8 mL.kg-1, 
and 2 had VT < 6 mL.kg-1. 
After model calibration, each individual patient in the cohort was simulated for 30 
minutes (or until reaching steady state) under mechanical ventilation with constant flow 
in the supine position. Figure 9 (A) and (B) compare the outputs of the simulator with 
the original data, expressed as median, interquartile range and actual range. Figure 10 
(A) and (B) shows the Bland-Altman plots for data points versus simulator outputs. To 
further test the reliability of the simulator, an additional validation procedure was 
performed in which PIP or mPaw were left out of the model calibration step, and the 
predicted model responses for these parameters were then checked against the data after 
the model matching stage. Figure 11 illustrates the results of the extended model 
validation on the development cohort by comparing the patient data against simulator 
predicted values expressed as median, interquartile range and actual range. The largest 
difference between the data and estimated values were observed when working with 
large pressure values which are considered unsafe in the clinical practice and violates the 
safety limits of this study as well (i.e. PIP > 35 cmH2O). These results confirm the 
capability of the simulator to accurately replicate multiple output values of the patients 










Table 2. Patient characteristics and mechanical ventilator settings presented as mean ± SD 
across the cohorts. 
 Patient Data & Ventilator Settings 
Parameters Age Weight FIO2 RR VT PEEP PF OI 
 y kg  bpm mL.kg-1 cmH2O   
Development 
Cohort 
3.1±0.4 14.7±3.2 0.6±0.2 25.9±6.0 7.8±1.6 9.8±2.6 154.7±76.7 13.0±7.1 
Test Cohort 1 1.4±0.3 10.3±1.9 0.6±0.2 26.6±4.4 8.1±1.2 8.7±1.9 178.4±61.6 9.4±4.5 
Test Cohort 2 5.3±6.0 18.2±15 0.6±0.3 23.7±8.0 11.1±1.0 10.8±2.6 157.4±67.8 15.7±12.9 
 Blood Gases & Airway Pressures 
 PaO2 PE’CO2 PaCO2 PIP mPaw 

































Table 3. Patient characteristics and mechanical ventilator settings for each individual patient in 
the development cohort. 
ID Age Weigh
t 
FIO2 RR VT PEEP PF OI PaO2 PE’CO2 PaCO2 PIP mPaw 
 (y) (kg)  (bpm) (mL.kg-1) (cmH2O)   (mmHg) (cmH2O) 
# 1 2.8 15 0.45 28 6.7 6 137 8 62 39 46 20 11 
# 2 2.8 14 0.5 20 6.3 14 152 14.5 76 54 72 34 22 
# 3 2.8 14.5 0.6 25 6.8 10 97 15.5 58 42 60 25 15 
# 4 2.8 17 0.5 20 4.5 10 236 5.9 118 37 53 26 14 
# 5 2.8 20 0.21 26 7 10 295 5.1 62 32 32 26 15 
# 6 3 9.5 1 40 8.9 8 78 16.7 78 62 65 22 13 
# 7 3 15 0.5 30 8.7 5 118 6.8 59 37 40 20 8 
# 8 3 13.6 0.5 16 7.4 10 178 7.3 89 43 59 21 13 
# 9 3 15 0.3 24 5.3 10 266 6.4 80 50 56 28 17 
# 10 3 13 0.4 28 7.8 12 230 7 92 59 60 25 16 
# 11 3.3 15 0.5 25 7.5 8 178 7.3 89 43 46 26 13 
# 12 3.5 14 0.35 34 10.3 8 274 5.1 96 54 56 28 14 
# 13 4 17.5 0.55 20 6.9 10 149 10.1 82 43 72 29 15 
# 14 4.3 19 0.6 24 7.2 14 111 18 67 41 56 41 20 
# 15 2.5 12.2 0.3 26 8.9 12 343 5.2 103 60 63 32 18 
# 16 3.7 15 0.4 22 6.7 6 170 5.9 68 48 51 24 10 
# 17 3.3 14 0.55 35 6.5 15 118 21.2 65 55 74 47 25 
# 18 2.8 27 0.8 24 6.7 12 73 24.7 59 33 42 32 18 
# 19 2.9 12 1 32 7.5 10 72 23.6 72 42 48 34 17 
# 20 3 9.5 1 37 8.9 12 78 29.5 78 50 79 42 23 
# 21 3 15 0.8 21 8.7 8 79 17.7 63.2 39 45 31 14 
# 22 3 13.6 1 20 9.6 8 57 26.3 57 30 39 24 15 
# 23 3 15 0.7 30 8 12 130 18.5 91 30 33 46 24 
# 24 3 13 0.4 27 7.5 12 150 12.7 60 72 75 41 19 
# 25 3.1 13 0.55 27 8.1 12 129 14.0 70.95 59 65 36 18 
# 26 3.1 13 0.75 21 8.8 8 112 10.7 84 62 64 20 12 
# 27 3.25 13 1 23 7.7 7 59 18.6 59 20 34 28 11 
# 28 3.3 15.5 0.35 23 8.4 8 237 6.8 82.95 47 59 36 16 
# 29 3.33 15 0.6 24 7.5 6 108 11.1 64.8 26 38 26 12 
# 30 3.5 14 0.35 20 13.6 12 226 8.4 79.1 35 36 37 19 
Mean 3.1 14.7 0.6 25.9 7.8 9.8 154.7 13.0 75.5 44.8 53.9 30.2 15.9 








Table 4. Patient characteristics and mechanical ventilator settings for each individual patient in 
test cohort 1. 
ID Age Weigh
t 
FIO2 RR VT PEEP PF OI PaO2 PE’CO2 PaCO2 PIP mPaw 
 (y) (kg)  (bpm) (mL.kg-1) (cmH2O)   (mmHg) (cmH2O) 
# 1 1.7 12 0.35 30.5 30.6 5 274 4.4 95.9 39 41 26 12 
# 2 1.5 9.8 0.5 23.5 23.3 8 230 4.8 115 47 48 20 11 
# 3 1.4 10 0.4 25 24.8 8 262 5.0 104.8 40 46 28 13 
# 4 1.67 8.8 0.35 25.5 25.7 8 274 5.1 95.9 39 52 30 14 
# 5 1.67 12 0.4 23 22.9 5 195 5.1 78 42 44 21 10 
# 6 2 10 0.5 20.5 20.6 10 226 5.3 113 39 44 17 12 
# 7 1.5 12 0.4 28.5 28.5 8 260 5.4 104 39 47 26 14 
# 8 2 14 0.5 20 20 8 236 5.9 118 39 41 22 14 
# 9 1.4 12.7 0.4 25 25.2 10 242 6.6 96.8 24 33 31 16 
# 10 1.1 10 0.4 29.5 29.4 12 246 7.3 98.4 35 41 37 18 
# 11 1.5 10.5 0.4 29 29 10 200 8.0 80 43 49 32 16 
# 12 1 6.5 0.65 28 28 8 160 8.1 104 54 57 26 13 
# 13 1.4 10 0.4 25.5 25.7 10 197 8.6 78.8 30 41 28 17 
# 14 1.33 8.8 0.45 39 39 8 169 8.9 76.05 39 51 30 15 
# 15 1.5 11 0.5 29 29 8 154 9.1 77 54 55 31 14 
# 16 1.75 11 0.5 23.5 23.4 11 197 9.1 98.5 36 54 39 18 
# 17 1.25 10 0.5 28 28.2 8 146 9.6 73 40 50 29 14 
# 18 1.4 7.5 0.8 22 21.9 8 124 9.7 99.2 46 47 23 12 
# 19 1 7.5 1 35 34.9 12 190 10.0 190 29 39 35 19 
# 20 1.8 12.3 0.7 24.5 24.6 8 135 10.4 94.5 45 58 25 14 
# 21 1.1 11.6 0.5 24 24.2 10 172 10.5 86 43 54 35 18 
# 22 1 8.2 0.8 31 31.2 5 93 10.8 74.4 51 57 24 10 
# 23 1.6 13 0.5 25.5 25.3 8 130 10.8 65 33 37 30 14 
# 24 1.5 10 0.65 21.5 21.7 10 123 12.2 79.95 50 54 29 15 
# 25 1.75 12.7 0.8 21.5 21.7 8 85 14.1 68 37 40 25 12 
# 26 1.1 10 0.9 26 26.1 10 105 16.2 94.5 34 37 35 17 
# 27 1.25 9 0.6 30.5 30.5 12 105 17.1 63 44 57 35 18 
# 28 1.25 7.7 1 30 30.2 8 65 24.6 65 41 61 34 16 
Mean 1.4 10.3 0.6 26.6 26.6 8.7 178.4 9.4 92.4 40.4 47.7 28.7 14.5 










Table 5. Patient characteristics and mechanical ventilator settings for each individual patient in 
test cohort 2. 
ID Age Weigh
t 
FIO2 RR VT PEEP PF OI PaO2 PE’CO2 PaCO2 PIP mPaw 
 (y) (kg)  (bpm) (mL.kg-1) (cmH2O)   (mmHg) (cmH2O) 
# 1 0.2 5.4 0.5 25 11.7 15 224 9.8 112 40 41 40 22 
# 2 0.5 6 0.35 35.5 11.1 7 194 6.2 67.9 24 31 28 12 
# 3 0.5 7.6 0.4 38.5 10 8 127 11.8 50.8 31 39 26 15 
# 4 0.6 6.8 0.5 39 10.4 6 156 10.3 78 35 63 37 16 
# 5 0.7 7 0.3 32 13 12 250 7.6 75 21 25 36 19 
# 6 0.8 8.5 0.4 23.5 10.4 12 197 8.6 78.8 39 40 25 17 
# 7 0.9 10 0.45 25.5 10.2 10 146 11.6 65.7 50 71 30 17 
# 8 1.25 7.7 1 24.5 10.4 8 65 24.6 65 41 61 34 16 
# 9 2 10 0.5 20.5 11.4 10 226 5.3 113 39 44 17 12 
# 10 3.2 14 0.6 20 10.7 12 148 10.8 88.8 36 38 30 16 
# 11 3.5 14 0.35 20.5 13.6 12 226 8.4 79.1 35 36 37 19 
# 12 3.5 13 1 28.5 10.8 12 59 50.8 59 48 49 42 30 
# 13 4.6 16.4 0.35 20.5 12.1 10 251 5.7 87.9 34 40 26 14 
# 14 8 14 0.45 16.5 11.9 12 153 11.8 68.9 31 35 27 18 
# 15 9.25 40 1 12 11.3 12 199 10.1 199 32 33 37 20 
# 16 10.2 45 1 13.5 10 12 59 33.9 59 30 36 40 20 
# 17 16.33 30 1 22 10 16 55 41.8 55 35 48 32 23 
# 18 17.1 55 0.7 12.5 10.9 12 180 10 126 27 30 28 18 
# 19 17.7 35 1 22 11.1 8 75 20 75 33 37 36 15 
Mean 5.3 18.2 0.6 23.7 11.1 10.8 157.4 15.7 84.4 34.8 41.9 32.0 17.8 




4.4.2. Evaluating strategies for implementing protective ventilation 
Figure 12 to Figure 13 show the effect of each strategy for implementing protective 
ventilation, in terms of its impact on VT, MP and ∆P. Similar reductions in average VT 
across the patient cohort were achieved using strategies 1-3 (15% (1.3 mL.kg-1), 12% (1 
mL.kg-1) and 14% (1.2 mL.kg-1), respectively). RR needed to be increased by a smaller 
amount (15%) for strategy 1, (versus 33% and 37% on average for strategies 2 and 3, 
respectively). After implementing any of the three strategies, the number of patients 
being ventilated using VT > 10 mL.kg-1 fell to zero. There were also reductions in the 
number of patients receiving VT in the ranges of 8–10 mL.kg-1 (-30 % for all strategies) 
and 6–8 mL.kg-1 (-18.8% for strategies 1 and 3, -12.5% for strategy 2). Correspondingly, 
the number of patients receiving VT in the range 4-6 mL.kg-1 rose from 6.7% to 33.3% 
in strategy 1 and to 30% in strategies 2 and 3, respectively. These average reductions 
were achieved despite the fact that there were 8 patients (4 severe PARDS, 4 moderate 
PARDS) whose baseline values of PaCO2 and PIP did not allow any of the strategies to 
be implemented without violating constraints. 
Figure 14 shows significant reductions in dynamic strain for strategies 1 to 3 (-20%, -
19% and -19%, respectively) with corresponding increases in static strain (+9%, +17% 
and +35%, respectively). The rise in static strain indicates larger lung volumes at end-
expiration. In strategy 3, the change in DC (shorter exhalation time) explains the higher 
static strain compared to the other two approaches. To rule out the possibility that 
higher static strains are due to breath-stacking, the difference between the inhaled tidal 
volume (VTi) and exhaled tidal volume (VTe) were examined in all strategies to detect 
possible incomplete exhalation. The change in end-expiratory lung volume was also 
monitored over a 3-hour time period. The results of both investigations confirm (see 
Figure 17) that the higher static strains are not a result of breath-stacking. Likely due to 
the higher RR, static and dynamic strain rates were higher in strategies 1 to 3 – Figure 







Figure 9. A comparison of the simulator outputs with the original patient data in panels (A) and 
(B), expressed as median, interquartile range and actual range. 
The ability of the simulator to accurately reproduce patient data was first verified by comparing 




Figure 10. Panels (A) and (B) show the Bland-Altman plots for simulator outputs and original 































































































































Figure 11. Results of the extended model validation on the development cohort by comparing 
the patient data against simulator estimated values 
Panels (A) and (B) show the results for leaving PIP out of the model matching step and 
subsequently predicting its value. Panels (C) and (D) show the results for leaving mPaw out of 
the model matching step and subsequently predicting its value. In (A) and (C) data are expressed 
as median, interquartile range and actual range whilst (B) and (D) present the Bland-Altman 


























































































































Figure 12. Development Cohort, panels illustrate the amount of tidal volume reduction. 
Box plot on the left (A) shows data as median, interquartile range and actual range while 
histogram on the right (B) demonstrates the distribution of all patients’ data before and after 
implementing different strategies. Similar reductions in average VT across the patient cohort 













































Figure 13. Development Cohort, panels illustrate the change in driving pressure (A)-(B) and 
mechanical power (C)-(D) before and after implementing different strategies. 
Box plots on the left (A)-(C) show data as median, interquartile range and actual range while 
histograms on the right (B)-(D) demonstrate the distribution of all patients’ data. Both ∆P and 





























































Differences emerged when considering the effect of each strategy on mechanical power. 
Strategy 1 produced no significant change (+1%; p=0.2, signed-rank test) but both 
strategies 2 and 3 resulted in large increases (+22% and +19%, respectively; both 
p<0.05). 
Amongst the four safety constraints, limits on PaCO2 and RR played the main role in 
restricting further reduction of VT. Limits on PaO2 were never reached. The changes in 
gas exchange, PE’CO2, PIP and mPaw caused by the VT reductions are presented in 
Figure 16. The values that are outside of the determined safety constrains represent 
those patients whose initial status violated one or other of the safety constraints. Figure 
15 (C) and (D) compares the levels of ventilatory dead space and dead space fraction 
(Eq.45) respectively, for all applied strategies. 




When strategy 4 (adjusting PEEP and VT to reduce ∆P) was applied, the PaCO2 limit 
was the only constraint precluding further reductions due to the strategy not 
compensating for MinV. Maintaining MinV is not possible using this strategy, as it 
requires increasing RR, leading to a rise in Pplat which in turn impedes reduction of ∆P. 
Consequently, this approach was only able to reduce ∆P in the 13 patients with the 
lowest initial PaCO2 levels. The average reduction in ∆P was -6% for all 30 patients in 
the dataset and -17% for the 13 patients on which this strategy could be applied. The 
corresponding changes in VT and PEEP were -7% and +10% respectively. This 
compares with changes in ∆P of -4%, +1% and +8% for strategies 1-3, respectively. 
Strategy 4 was the only approach that produced a significant reduction in mechanical 









Figure 14. Development Cohort, panels compare the dynamic strain (A)-(B) and static strain 
(C)-(D) before and after implementing different strategies. 
Box plots on the left (A)-(C) show data as median, interquartile range and actual range while 
histograms on the right (B)-(D) demonstrate the distribution of all patients’ data. Strategy 3 had 
























































Figure 15. Development Cohort, panels compare the dynamic strain rate (A), static strain rate 
(B), dead space (C) and dead space fraction (D) before and after implementing different 
strategies. 
Box plots show data as median, interquartile range and actual range. All strategies increased 






















































Figure 16. Panels (A) and (B) represent the variations in patients’ responses to tidal volume 
reduction strategies. 
The values that are outside the specified safety constraints are from those patients who had such 
values at baseline. Box plots show data as median, interquartile range and actual range. Amongst 
the four safety constraints, limits on PaCO2 and RR played the main role in restricting further 










































Figure 17. Figure shows the difference between the average inhaled tidal volumes (VTi) and 
exhaled tidal volumes (VTe) (red triangles) as well as the change in end-expiratory lung volume 
(EELV) (blue circles) over a 3h time period. 

























Average change in EELV
Average differenece between VTi and VTe
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4.4.3. Additional test cohorts 
To test the utility and generalisability of our results, the same 4 strategies are applied to 
two separate test cohorts of PARDS patients from the CHOP dataset. For both test 
cohorts, the same fidelity in matching simulated outputs to patient data was observed as 
with the initial development cohort. Two patients in Test Cohort 1 and three patients in 
Test Cohort 2 had baseline values of PaCO2 and PIP that would not allow any of the 
proposed strategies to be implemented. 
Similar trends emerged in terms of achieving more protective ventilation for all 4 
strategies with these additional datasets (Figure 18 and Figure 24). Strategy 1 produced 
the largest average reductions in VT (-22% in Test Cohort 1, -28% in Test Cohort 2) and 
dynamic strain (-20% in Test Cohort 1, -27% in Test Cohort 2), with the lowest 
corresponding increase in static strain (+1% in Test Cohort 1, +3% in Test Cohort 2). 
Strategy 1 produced a small reduction in mechanical power (-4% in both cohorts) and 
significant reductions in ∆P (-13% and -16%). Although strategies 2 and 3 achieved 
reductions in VT, ∆P and dynamic strain; this came at the cost of higher increases in 
static strain than required by strategy 1. Both strategies 2 and 3 also produced large 
increases in mechanical power. Finally, strategy 4 produced significant decreases in VT, 
dynamic strain and ∆P in both cohorts, and the largest decreases in mechanical power (-
10% in Test Cohort 1, -23% in Test Cohort 2). Over the three cohorts analysed, Test 
Cohort 2 (initial VT > 10 mL.kg-1) showed the greatest potential for improvements in 








Figure 18. Test Cohort 1&2, panels illustrate the amount of tidal volume reduction. 
Box plots on the left (A)-(C) show data as median, interquartile range and actual range while 
histograms on the right (B)-(D) demonstrate the distribution of all patients’ data before and 
after implementing different strategies. All strategies significantly reduced VT. Strategy 1 



































































































Figure 19. Test Cohort 1, panels illustrate the change in driving pressure (A)-(B) and mechanical 
power (C)-(D) before and after implementing different strategies. 
Box plots on the left (A)-(C) show data as median, interquartile range and actual range while 
histograms on the right (B)-(D) demonstrate the distribution of all patients’ data. Both ∆P and 






















































































































Figure 20. Test Cohort 1, panels compare the dynamic strain (A)-(B) and static strain (C)-(D) 
before and after implementing different strategies. 
Box plots on the left (A)-(C) show data as median, interquartile range and actual range while 
















































































































Figure 21. Test Cohort 1, panels compare the dynamic strain rate (A), static strain rate (B), dead 
space (C) and dead space fraction (D) before and after implementing different strategies. 
Box plots show data as median, interquartile range and actual range. All strategies increased 




































































































Figure 22. Test Cohort 2, panels illustrate the change in driving pressure (A)-(B) and mechanical 
power (C)-(D) before and after implementing different strategies. 
Box plots on the left (A)-(C) show data as median, interquartile range and actual range while 
histograms on the right (B)-(D) demonstrate the distribution of all patients’ data. Both ∆P and 
























































































































Figure 23. Test Cohort 2, panels compare the dynamic strain (A)-(B) and static strain (C)-(D) 
before and after implementing different strategies. 
Box plots on the left (A)-(C) show data as median, interquartile range and actual range while 
histograms on the right (B)-(D) demonstrate the distribution of all patients’ data. All strategies 
















































































































Figure 24. Test Cohort 2, panels compare the dynamic strain rate (A), static strain rate (B), dead 
space (C) and dead space fraction (D) before and after implementing different strategies. 
Box plots show data as median, interquartile range and actual range. All strategies increased 





























































































Four separate strategies have been developed and tested for achieving lung protective 
ventilation in PARDS. A strategy of maintaining MinV allowed for greatest reduction in 
VT with small decreases in mechanical power.  A strategy of minimizing ΔP resulted in 
larger reductions in mechanical power, with smaller reductions in VT.  Conversely, 
strategies aimed at maintaining constant alveolar ventilation, either by manipulating DC 
or inspiratory flow, are capable of reducing VT and ΔP, they come at the expense of 
increasing power.  Although some previous studies utilising a uniform low value of VT 
showed deleterious effects [140], here VT was progressively reduced in patients only as 
long as it did not violate safety constraints on gas exchange or cause any damaging 
effects. Similarly, while increasing RR in isolation could potentially exacerbate VILI 
[164, 165], here only RR is increased by modest amounts to compensate for 
simultaneous reductions in VT. Our results suggest that there is significant scope for 
safely adjusting ventilator settings in PARDS to mitigate VILI and demonstrate the 
utility of simulation to establish testable hypotheses in ventilated children. 
Albuali et al. [146] suggested lower VT was associated with lower mortality in a study of 
164 children with PARDS. However, this retrospective study made no allowance for 
trends showing general improvement in PARDS survival rates over the last decades 
[149, 166]. Conversely, in a prospective, multicentre observational study, Erickson et al. 
[148] found higher VT to be associated with lower mortality. Furthermore, a number of 
other retrospective and prospective studies failed to identify any significant relationship 
between VT and mortality in PARDS [147, 167]. A meta-analysis of observational 
studies [145] could not establish an association between VT and mortality in ventilated 
children, and both PALICC [136] and PEMVECC [139] rely primarily on adult data for 
their recommendations. 
In 2015, PALICC released the first recommendations specifically tailored to PARDS 
[136], and addressed a number of current issues in patient treatment. Strategies limiting 
VT and plateau pressure were marked under “weak agreement.” In addition, a survey on 
stated practice pattern found that although paediatricians theoretically concurred with 
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adult guidelines to ventilate with lower VT and pressure constraints, in actual practice, 
over 25% of PARDS patients are ventilated with VT > 10 mL kg-1 [168], and likely 
higher in obese children when adjusting for ideal body weight. Likewise, a recent study 
by Ward et al. [169] revealed poor adherence rates of only 32% (using a VT cut-off of 
6.5 mL kg-1) and 58% (using a cut-off of 8 mL kg-1) for using low VT.  
Despite this, mortality rates in PARDS have improved over the last two decades, part of 
which may be related to adoption of lung-protective ventilation strategies and 
extrapolation from adult ARDS literature.  Continued resistance to lung-protective 
ventilation in PARDS, particularly use of VT > 10 mL kg-1, may reflect concerns 
regarding whether VT and ventilator pressures can be safely reduced in this population.  
Here, the feasibility of adjusting ventilator settings to mitigate VILI within reasonable 
safety parameters for gas exchange and RR is demonstrated.  The reductions achieved 
are most pronounced in subjects with VT > 10 mL.kg-1 and appear to be generalizable 
throughout the entire age range and severity encountered in PARDS. While studies of 
ΔP and mechanical power limits are in their infancy, preliminary data suggest 
“thresholds” above which these values are associated with worse outcomes [143, 170].  
Analysis of our dataset shows that these thresholds are currently being exceeded in 
many subjects, particularly in children with VT > 10 mL kg-1. 
Static strain represents the initial displacement of the lungs from their original position 
due to PEEP at the start of ventilation and subsequently stays constant during 
ventilation unless PEEP is changed. It has been shown that the lung can tolerate 
increased static strain, provided that the total lung capacity is not exceeded, and that 
dynamic strain is likely to be more injurious [161, 163]. The change in lung strain is also 
correlated with the recruited volume of the lung. A recent study showed that lung 
recruitment causes reduction in dynamic strain while increasing static strain [163]. 
Hence, both the changes in static and dynamic strain observed in our results suggest 
general improvement in lung recruitment as a result of the changes to ventilator settings. 
Strategy 4 resulted in reduced mechanical power. The original power equation (Eq.44) 
by Gattinoni et al. can be simplified and re-written as the equation below [142]: 
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MP = RR × VT × (PIP − 0.5Pplat + 0.5PEEP) = RR × VT × (PIP − 0.5∆P) (46) 
Considering the above equation, it can be expected that an increment in inspiratory flow 
(Eq.39) leads to an increase in power as long as the cause of the change in flow is MinV 
(i.e. RR·VT). However, when MinV was kept constant and a smaller DC raised the flow, 
the resultant change in power depends on how PIP and Pplat respond to the adjustment 
– i.e. specifically the change of (PIP-0.5ΔP). As a result, it cannot be concluded that a 
greater flow would always lead to a rise in the power. Moreover, it should be noted that 
MinV directly impacts the power, not the flow itself. For instance, patients were 
ventilated with the same flow in strategy-1 and strategy-3, while the latter has a larger 
MinV, and so higher power. 
The study has a number of limitations. Data were derived from a single institution, and 
while severity of PARDS and outcomes were similar to other cohorts, generalizability 
remains to be demonstrated. To minimise possible confounding factors, the model is 
currently configured to represent patients that are fully sedated under mechanical 
ventilation, therefore autonomic reflex modules in the model were not utilised. The 
model also does not include the effect of inflammatory mediators commonly found in 
PARDS, which are difficult to quantify and isolate in clinical settings. As the model is 
computational in nature, it does not provide any direct histological or biological 
evidence of the effects of the proposed ventilation strategies on VILI markers, and 
therefore further animal and/or human studies should be performed to provide 
conclusive evidence of their relative effectiveness in achieving more protective 
ventilation. As adolescents may be diagnosed with either Berlin or PALICC criteria 
[171], it is unclear whether they would be more appropriately managed with our 
protocol, or an adult version. The model was developed to focus on VILI, and those 
chose to use PaCO2, rather than pH. While this may not entirely reflect clinical practice, 
in which pH is monitored alongside PaCO2, the simulator cannot accommodate 
something as variable as pH, which is often modified by entire non-ventilator 
interventions, such as volume resuscitation or exogenous bicarbonate. 
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Chapter 5:  
 
 
Evaluating the utility of driving pressure 
and mechanical power to determine 
optimally protective ventilator settings in 
two cohorts of adult and paediatric ARDS 
patients  
5.1. Summary 
Mechanical power and driving pressure have recently been proposed as indicators, and 
possibly drivers, of ventilator-induced lung injury. In this chapter, the utility of these 
different measures as targets to derive maximally protective ventilator settings is tested. 
The computational simulator was matched to individual patient data and used to 
identify strategies that minimize ∆P, MP and a modified version of MP (MMP) that 
removes the direct linear positive dependence between MP and PEEP. Data from the 
low tidal volume arm of the ARDSnet trial (N=100) and from an observational study of 
paediatric ARDS from the Children’s Hospital of Philadelphia (N=77 – the same data 
as used in Chapter 4) was used for the study. Global optimization algorithms evaluated 
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more than 26.7 million changes to ventilator settings (approximately 150,000 per 
patient) to identify strategies that minimize ∆P, MP or MMP. Large average reductions 
in ∆P (23%-Paediatric, 23%-Adult), MP (44%-Paediatric, 66%-Adult) and MMP (61%-
Paediatric, 67%-Adult) were achievable in both cohorts when oxygenation and 
ventilation were allowed to vary within specified safe ranges. Reductions in ∆P (12%-
Paediatric, 2%-Adult), MP (24%-Paediatric, 46%-Adult) and MMP (44%-Paediatric, 
46%-Adult) were still achievable even when no deterioration in gas-exchange was 
allowed. Minimum values of MP and MMP in both cohorts were produced by 
increasing VT and decreasing respiratory rate. Minimising MMP rather than MP resulted 
in higher values of PEEP in both cohorts. In the paediatric cohort, minimum ∆P was 
achieved by reducing VT and increasing RR and PEEP. The adult dataset had limited 
scope for further reducing VT, but ∆P could still be significantly reduced by increasing 
PEEP. Our analysis identified different ventilatory strategies that minimized ∆P or MP 
consistently across adult and paediatric datasets. Minimizing standard and alternative 
formulations of MP led to significant increases in VT. Targeting ∆P for minimisation 
resulted in ventilator settings that also reduced MP and MMP, but not vice versa. 
5.2. Introduction 
Mechanical power (Eq.44) [142–144], and driving pressure (Eq.40) [141], have recently 
been proposed as important measures of VILI in acute respiratory distress syndrome. 
Arguments for the importance of MP focus on the biophysical role of energy 
(stress×strain) and dynamics (rates of airway pressure change and cycling frequency) in 
the injurious potential of mechanical ventilation [144], whereas arguments for the 
centrality of ∆P are supported by statistical and computational analyses of clinical trial 
data that show strong correlations between the level of ∆P applied and relative risk of 
mortality [84, 141]. However, the rationale for both MP and ∆P rely on re-analyses of 
adult ARDS cohorts, and while initial studies are in progress (NCT03616704 and 




To date, there has been no randomized trial to determine the appropriate application of 
protective ventilation in PARDS, and observational studies are unclear, with conflicting 
results [145–148].  Ventilator management in children is often extrapolated from adults, 
with uncertain applicability [172]. PARDS has a distinct epidemiology, with different 
inciting aetiologies and predictors of outcome [137, 173], relative to adults, necessitating 
specific investigations in children. Overall, even less evidence is available for children 
regarding the utility of either MP or ∆P as metrics of VILI or as modifiable ventilator 
parameters. 
To investigate the above issues, the high-fidelity computational simulator is employed 
and matched to individual patient data from two separate cohorts, paediatric and adult. 
High-fidelity simulation holds the potential to develop, test, and directly compare 
ventilation strategies prior to exposing vulnerable patients to potentially damaging 
interventions. Global optimization algorithms, implemented on high-performance 
computing clusters, were used to evaluate more than 26.7 million different changes to 
the baseline ventilator settings to identify those that minimized, in each individual 
simulated patient, ∆P, MP, and a modified formulation of MP (MMP) based on 
concerns [174] regarding the direct, positive, linear effect of PEEP on MP in the 
original MP equation. Changes to ventilator settings were constrained within specified 
limits, and maximally protective settings optimizing ∆P, MP, and MMP were calculated 
for two different scenarios (a) allowing, within safe limits, some deterioration in patient 
gas-exchange from baseline values, and (b) without allowing any deterioration in patient 
gas exchange. The primary aim of this study was to assess the scope for achieving more 
protective ventilation by separately minimising ∆P, MP or MMP. A secondary goal of 
the study was to investigate to what extent protective ventilation strategies identified for 
the paediatric cohort were consistent with those computed for the adult cohort. 
Chapter 5 
 79 
5.3. Materials and Methods 
5.3.1. Patient selection 
Paediatric cohort  
Patients were selected from an ongoing (2011 onwards) observational prospective 
cohort [149] of intubated children meeting Berlin criteria for ARDS from the Children’s 
Hospital of Philadelphia (CHOP). Seventy-seven subjects between 1 month and 18 
years of age (Mean: 3.1, SD: 3.3, 23% severe, 44% moderate and 33% mild ARDS), 
ventilated via cuffed endotracheal tube during neuromuscular blockade, were selected. 
For full details see Section 4.3.1. 
Adult cohort  
Data were extracted from 100 adult ARDS patients randomly selected (14% severe, 
66% moderate, 20% mild) from the low tidal volume arm of the ARMA trial [4]. Access 
to the data was granted by the Biologic Specimen and Data Repository Information 
Coordinating Centre (BioLINCC) of the National Heart, Lung and Blood Institute 
(NHLBI). The data were provided in a de-identified state, and informed consent was 
not required. All patients received mechanical ventilation in assist-control ventilation 
mode. 
5.3.2. Simulator calibration to patient data 
Analyses were carried out using the simulator described in Chapter 2 and Chapter 4 (see 
Section 2.4 and Section 4.3.2). The simulator was matched to individual patient data 
using advanced global optimisation algorithms (see Section 3.3.1).  
5.3.3. Maximally protective ventilation as a constrained optimisation problem 
After matching the model to each individual patient, the potential for achieving 
maximally lung-protective (but acceptably effective) ventilation in these patients was 
investigated by formulating and numerically solving several different optimisation 
problems. For each individual patient, advanced global optimisation algorithms 
implemented on high-performance computing clusters is used to exhaustively search 
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through more than 26.7 million different changes to the reported ventilator settings – 
namely VT, RR, FIO2, PEEP and duty cycle DC (inspiratory-to-total time ratio) to 
identify which settings produced minimum values of the following quantities: 
• Driving pressure (Eq.40); 
• Mechanical Power (Eq.44); 
• A modified version of mechanical power (MMP) [174], given by: 
MMP = 0.098 × RR × VT
2 × [0.5 × ELrs + RR ×
(1 + I: E)
60 × I: E
× Raw] (47) 
which removes the direct linear, positive dependence between MP and PEEP [174]. 
To ensure the relevance of these optimisation problems to clinical practice, it is 
necessary to constrain the search for maximally protective settings to include only those 
that do not compromise the provision of adequate oxygenation and ventilation. This is 
achieved firstly by defining upper and lower allowable limits for the ventilation settings 
themselves (Table 6), and secondly by defining allowable limits for the values of patient 
blood gases PaO2 and PaCO2 and peak inspiratory pressure (Table 6) produced by the 
settings. The upper limit of RR in adults is set slightly higher than that in ARDSnet trial 
(40 vs 35 bpm) as higher RRs were observed at the baseline and were considered a 
plausible limit by clinicians. Ventilation settings that minimized ∆P, MP and MMP while 
keeping values of PaO2, PaCO2 and PIP within their specified limits were then 
computed for each patient (Approach 1). In the paediatric cohort, these limits were 
based on those used in the ARDSnet trial, adapted to match paediatric conventions 
[147, 148, 172, 175]. As the paediatric cohort was developed using decelerating flow, as 
is most common in paediatrics [176], PIP was used as a constraint rather than Pplat. 
When data indicated that a patient’s initial ventilator state did not comply with one or 
more of the specified safety limits, changes to the settings were only made if they led to 
an improvement in the relevant parameters (e.g. reducing PaCO2 or PIP). 
As an alternative strategy, it is also investigated whether changes to ventilator settings 
could be found that minimized ∆P, MP and MMP without resulting in any deterioration 
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in PaO2 and PaCO2 from their baseline values (Approach 2). An upper limit of 35 
cmH2O was again applied for PIP in the paediatric cohort. Due to relatively higher 
baseline PIP values in adults, the upper limit of PIP was set to the corresponding 
baseline values for these patients – Figure 33 and Figure 34. 
5.3.4. Statistical analysis 
Data are presented as Mean ± SD, or shown graphically using median, interquartile and 
total ranges. To avoid violation of underlying distribution assumptions, variables were 
compared using nonparametric statistics when appropriate (i.e. Wilcoxon signed-rank 
test). A two-sided p-value of < 0.05 was considered significant. 
5.4. Results 
5.4.1. The simulator accurately represents individual patient data 
The ability of the simulator to reproduce patient data was verified by comparing its 
responses (PaO2 and PaCO2) against data on the responses of patients from both 
cohorts. After model calibration, each individual patient in the cohort was simulated for 
30 minutes (or until reaching steady state) under volume controlled mechanical 
ventilation with constant flow in the supine position. The results of matching for the 
paediatric cohort has been presented in Chapter 4 (see Figure 9 and Figure 10). For 
adult cohort, Figure 25 (A) and (C) compares the outputs of the simulator with the 
original data, expressed as median, interquartile range and actual range. Also, Figure 26 
(A) and (B) shows the Bland-Altman plots for data points versus simulator output 
values. These results confirm the capability of the simulator to accurately replicate 
multiple output values of the patients included in both cohorts across a range of 










Table 6. Allowable ranges of variation for ventilator parameters (approach 1 and 2) and 
predefined safety constraints (approach 1). 
 Paediatric Adult 
 Lower Limit Upper Limit Lower Limit Upper Limit 
Allowable ranges for ventilator parameters 
PEEP (cmH2 O) 5 18 5 20 
RR (bpm) 10 40 10 40 
VT (mL.kg-1) 3 12 3 10 
DC 0.3 0.6 0.2 0.8 
FIO2 0.21 1 0.21 1 
Predefined safety constraints 
PaO2 (mmHg) 60 120 55 100 
PaCO2 (mmHg) - 60 - 60 








Figure 25. A comparison of the simulator outputs with the original adult patient data in panels 
(A) and (B), expressed as median, interquartile range and actual range. 
The ability of the simulator to reproduce patient data was verified by comparing its responses 




Figure 26. Panels (A) and (B) show the Bland-Altman plots for simulator outputs and original 














































































































R = 87.7 Pplat
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5.4.2. Reductions in ∆P, MP and MMP were achieved in both cohorts 
When ABGs were allowed to vary within pre-specified ranges given in Table 6, average 
maximum reductions in ∆P of 3.0±2.2 cmH2O (23%) compared to baseline values in 
the paediatric cohort and 3.2±2.1 cmH2O (23%) in the adult cohort were achievable – 
Figure 27. Reductions in ∆P of over 1 cmH2O were achieved in 95% of paediatric and 
82% of adult patients. The corresponding reductions when targeting MP were 3.3±2.6 
J.min-1 (44%) in the paediatric cohort (87% of whom had MP reduced by more than 
20%) and 21.0±5.4 J.min-1 (66%) in the adult cohort, with all patients reducing MP by 
over than 20%. When targeting the modified formulation of mechanical power MMP, 
the reductions achievable were 3.7±2.3 J.min-1 (61%) in the paediatric cohort and 
15.2±4.9 J.min-1 (67%) in the adult cohort (reductions of more than 20% were achieved 
in 95% and 99% of the paediatric and adult cohorts respectively). Reductions were 
statistically significant in all groups (Wilcoxon signed-rank test p<0.05). In all the above 
cases, more protective ventilation was achieved with no significant deterioration in 
patient oxygenation (PaO2), although values of patient PaCO2 did consistently tend to 
increase towards the upper limits – Figure 28. In both cohorts, settings that minimized 
∆P also reduced MP and MMP, whereas settings that minimized MP and MMP 
increased ∆P (largely due to the resulting increases in VT). 
When the optimisations were constrained to allow no deterioration in gas exchange (i.e. 
only changes to ventilator settings that maintained, or improved, PaO2 and PaCO2 with 
respect to their baseline values were allowed), reductions were achievable in ∆P of 
1.6±1.4 cmH2O (12%) compared to baseline values in the paediatric cohort (58% had 
reductions of more than 1 cmH2O) and 0.4±1.0 cmH2O (2%) in the adult cohort (16% 
had reductions of more than 1 cmH2O) – Figure 29. The corresponding reductions 
when targeting MP were 1.7±1.4 J.min-1 (24%) in the paediatric cohort and 14.4±4.9 
J.min-1 (46%) in the adult cohort, with 57% of paediatric and 98% of adult patients 
having MP reduced by more than 20%. When targeting MMP, the reductions achievable 
were 2.5±1.5 J.min-1 (44%) in the paediatric cohort (90% of whom had reductions of 
more than 20%) and 10.3±4.4 J.min-1 (46%) in the adult cohort, with 97% achieving 
reductions of more than 20%. Reductions were statistically significant in all cases 
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(Wilcoxon signed-rank test p<0.05). The individual results for both cohorts are shown 
in Figure 31 and Figure 32. 
5.4.3. Minimum values of ∆P and MP are achieved by distinct ventilation strategies 
Minimum values of MP in both adult and paediatric cohorts were produced by changes 
to ventilator settings that increased VT (Paediatric: 1.4±1.8 mL.kg-1 (+19%), Adult: 
1.9±1.1 mL.kg-1 (+34%)), decreased RR (Paediatric: -8.6±5.1 bpm (-34%), 
Adult: -15.6±5.0 bpm (-56%)), set DC at or close to its specified upper limit of 0.6, and 
set PEEP at or close to its specified lower limit of 5 cmH2O – Figure 35 to Figure 38. 
FIO2 increased in both paediatric and adult cohorts (Paediatric: +39%, Adult: +26%).  
Similar changes in VT, RR and DC were observed in both cohorts when targeting the 
MMP. As expected, minimising MMP rather than MP resulted in higher values of PEEP 
in both paediatric and adult cohorts (Paediatric: 2.9±4.6 cmH2O (+39%), Adult: 3.5±5.0 
cmH2O (+52%)) along with lower values of FIO2 in paediatric patients (-21%). 
In the paediatric cohort, minimum ∆P was achieved by reducing VT (1.3±1.6 mL.kg-1 
(-15%)) while increasing RR and PEEP (2.3±8.2 bpm (+11%) and 2.4±4.5 cmH2O 
(+34%) respectively). In the adult cohort, no significant reductions in VT were possible 
(unsurprisingly, since the selected patients were from the low VT arm of the ARDSnet 
trial), but ∆P could still be reduced, principally by increasing PEEP (2.2±3.5 cmH2O 
(+32%)). No substantial changes in DC were observed in either cohort when targeting 
∆P. Patterns of changes in ventilator settings were strongly consistent in most cases 
between Approach 1 (allowing some deterioration in blood gas values) and Approach 2 
(allowing no deterioration in blood gas values), although when minimising ∆P in 
paediatric patients, Approach 2 produced higher values of FIO2 than Approach 1, in 




Figure 27. Approach 1 – Change in driving pressure, mechanical power and modified 
mechanical power when minimising different targets (i.e. ∆P, MP and MMP) and allowing some 
deterioration in patient gas-exchange. Box plots demonstrate data as median, interquartile range 
















































































Figure 28. Approach 1 – Change in PaO2, PaCO2 and pH when minimising different targets and 
allowing some deterioration in patient gas-exchange. Panels (A) to (C) show results for the 
paediatric cohort and (D) to (F) for the adult cohort. Box plots demonstrate data as median, 













































































Figure 29. Approach 2 – Change in driving pressure, mechanical power and modified 
mechanical power when minimising different targets (i.e. ∆P, MP and MMP) and allowing no 
deterioration in gas-exchange. Panels (A) to (C) show results for the paediatric cohort and (D) 
















































































Figure 30. Approach 2 – Change in PaO2, PaCO2 and pH when minimising different targets and 
allowing no deterioration in gas-exchange. Panels (A) to (C) show results for the paediatric 
cohort and (D) to (F) for the adult cohort. Box plots demonstrate data as median, interquartile 

















































































Figure 31. Paediatric Patients – Initial and minimised values of ∆P, MP and MMP in individual 
patients. 
Panels (A) to (C) show results for Approach1 (i.e. allowing some deterioration in patient gas-






















































































































































































































Figure 32. Adult Patients – Initial and minimised values of ∆P, MP and MMP in individual 
patients. 
Panels (A) to (C) show results for Approach1 (i.e. allowing some deterioration in patient gas-






















































































































































































































Figure 33. Approach 1 – Change in peak pressure and plateau pressure when minimising 
different targets (i.e. ∆P, MP and MMP) and allowing some deterioration in patient gas-
exchange. 
Panels (A) to (B) show results for the paediatric cohort and (C) to (D) for the adult cohort. Box 
plots demonstrate data as median, interquartile range and actual. Minimising MP was associated 





























































Figure 34. Approach 2 – Change in peak pressure and plateau pressure when minimising 
different targets (i.e. ∆P, MP and MMP) and allowing no deterioration in gas-exchange. 
Panels (A) to (B) show results for the paediatric cohort and (C) to (D) for the adult cohort. Box 
plots demonstrate data as median, interquartile range and actual. Minimising MP was associated 


























































Figure 35. Approach 1 – Figure shows the changes in tidal volume, respiratory rate and PEEP 
that minimize different targets (i.e. ∆P, MP and MMP). 
Panels (A), (C) and (E) show results for the paediatric cohort while (B), (D) and (F) are for the 
adult cohort. Box plots demonstrate data as median, interquartile range and actual. Minimising 
∆P was achieved by lowering VT and increasing RR and PEEP. Minimising MP led to higher 













































































Figure 36. Approach 2 – Figure shows the changes in tidal volume, respiratory rate and PEEP 
that minimize different targets (i.e. ∆P, MP and MMP). 
Panels (A), (C) and (E) show results for the paediatric cohort while (B), (D) and (F) are for the 
adult cohort. Box plots demonstrate data as median, interquartile range and actual. Minimising 
∆P was achieved by lowering VT and increasing RR and PEEP. Minimising MP led to higher 

















































































Figure 37. Approach 1 – Figure shows the changes in FIO2 and duty cycle that minimize 
different targets (i.e. ∆P, MP and MMP). 
Panels (A) and (C) show results for the paediatric cohort while (B) and (D) are for the adult 
cohort. Box plots demonstrate data as median, interquartile range and actual. Minimising MP 
was associated with higher levels of FiO2. Also, the values of duty cycle were close to its upper 












































Figure 38. Approach 2 – Figure shows the changes in FIO2 and duty cycle that minimize 
different targets (i.e. ∆P, MP and MMP). 
Panels (A) and (C) show results for the paediatric cohort while (B) and (D) are for the adult 
cohort. Box plots demonstrate data as median, interquartile range and actual. Minimising MP 
was associated with higher levels of FiO2. Also, the values of duty cycle were close to its upper 







































Our results provide several new insights into the types of ventilation strategies that are 
likely to minimize different indicators of VILI in ARDS patients. A high degree of 
consistency was observed in settings that minimized ∆P, MP and MMP across the 
diverse patient cohorts in both datasets, providing grounds for optimism that strategies 
for maximally protective ventilation could be developed that would be widely applicable 
in ARDS. 
Perhaps the most counterintuitive result is that maximum reductions in MP and MMP 
are consistently achieved by changes to ventilator settings that involve increasing VT 
(Figure 27) since from both the standard (Eq.44) and modified (Eq.47) formula for MP 
it seems obvious that lowering VT should lower MP.  Crucially, however, this ignores 
the impact of incorporating constraints on allowable deterioration in patient gas-
exchange, which would always exist in treatment strategies implemented at the bedside. 
These constraints, combined with the complexity of making simultaneous adjustments 
to multiple ventilator settings, add a host of other trade-offs, that render the optimal 
combination of ventilator settings almost impossible to predict based on clinical 
intuition alone. The presented results point to a complex interplay between ventilator 
parameters which would support the development of a closed-loop system that can 
incorporate direct patient inputs, thereby providing individualised safe and effective 
mechanical ventilation based on the proposed safety limits and target parameter to 
minimise, input by clinicians at the bedside. However, when designing closed-loop 
system the model needs to consider the dynamic state of a patient so tuning itself as the 
patient physiology changes over time (i.e. the patient gets worse/better). Furthermore, 
the findings can be used to design bespoke guidelines on appropriate ventilator settings 
for clinical trials on low vs high ∆P, MP or MMP. These guidelines would be based on a 
variety of individual patient data such as disease severity, age, etc. rather than a one-size-
fits-all instruction. 
In the paediatric cohort, minimum values of ∆P were consistently achieved by reducing 
VT and increasing RR and PEEP. Interestingly, this strategy has much in common with 
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the ARDSnet trial protocol, which lowered VT while increasing RR. Some have 
postulated that this combination led to increased intrinsic (and hence total) PEEP [177], 
which may have contributed to the mortality benefit in this trial. However, it should be 
noted that subsequent trials of higher versus lower PEEP have not demonstrated a 
mortality benefit in heterogeneous ARDS populations [156, 178–180]. Since the selected 
patients in the adult cohort were from the low VT arm of the trial, no further reductions 
in VT were possible without violating imposed constraints on gas exchange. However, 
∆P could still be significantly reduced in this cohort by moderately increasing PEEP. 
Our findings provide novel and important insights into the challenges of using either 
∆P or MP to develop protective lung ventilatory strategies. In our models, targeting 
reductions in ∆P led to increased RR and increased PEEP. While a strong association 
between higher ∆P and mortality has been demonstrated in multiple datasets, including 
by Amato et al [141], and in the LUNG SAFE global patient cohort [181], ∆P was not a 
therapeutic target in these patients, and causality remains elusive. There is data 
suggesting that increasing RR [165] and PEEP [182] beyond safe thresholds can be 
deleterious in injured lungs. Furthermore, in the Alveolar Recruitment for ARDS Trial 
(ART) clinical trial [183], a ventilatory strategy that decreased ∆P resulted in increased 
mortality. The usefulness of targeting ∆P directly thus remains to be demonstrated. 
These concerns also apply to strategies that target reductions in MP. While MP 
represents a more complete attempt to describe the contributions of multiple 
parameters to VILI by invoking their “energy cost,” the relative contributions of the 
different parameters (i.e., their relatively equal “weightings” in the formula) remains the 
subject of debate. An example is the controversy around how PEEP contributes to MP 
[174]. Our results show that different formulations of the MP equation lead to different 
optimal strategies; specifically, higher PEEP when optimizing MMP. Our finding that 
strategies that minimize MP and MMP increase VT highlights the challenges of targeting 
one specific parameter in designing protective ventilatory strategies. This is particularly 
important given the findings from recent pre-clinical animal studies that, for the same 
MP, strategies employing higher rather than lower VT had increased injury [184, 185]. 
All these findings highlight the need for prospective validation of ventilator strategies 
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that target reduced MP. Of importance, computational modelling of the impact of 
targeting these parameters (or combinations of different VILI indices) may identify 
promising non-intuitive combinations of ventilator settings for clinical testing, and also 
allow more effective stratification of patient populations by revealing differences in the 
effects of ventilation strategies across heterogeneous patient populations. 
The study has a number of limitations. The paediatric dataset was derived from a single 
institution, and while the severity of ARDS and outcomes were similar to other cohorts, 
generalizability cannot be assumed. To minimise confounding, the model was 
configured to represent patients who are fully sedated and/or paralyzed; therefore, 
autonomic reflex modules were not utilised. The model also does not include the effect 
of inflammatory mediators, which are difficult to quantify and to isolate in clinical 
settings. As the model is computational in nature, it does not provide any direct 
physiologic, histological or biological evidence of the effects of the proposed ventilation 
strategies on VILI, and further animal and human studies should be performed to 
provide conclusive evidence of their effectiveness in achieving more protective 
ventilation. The model was developed to focus on ventilator settings affecting VILI; 
thus, constraints are set on PaCO2 rather than pH, which is often modified by entirely 
non-ventilator interventions, such as volume resuscitation or exogenous bicarbonate. 
However, the study also has several unique strengths. Over 26.7 million distinct 
combinations of ventilator settings were implemented and evaluated on two separate 
cohorts of patients with ARDS. It is difficult to imagine such a comprehensive 
exploration of different ventilation strategies ever being possible via animal or clinical 
trials. The study also allows a direct comparison of the effects of protective ventilation 
strategies in adult and paediatric ARDS patients. Our results clearly demonstrate the 
utility of pilot studies using high-fidelity simulation to assess novel interventions 
targeting MP or ΔP (or any other VILI indicator), and hence to inform the design of 




Chapter 6:  
 
 
Computational simulation of mechanically 
ventilated neonates 
6.1. Summary 
This chapter presents preliminary results on the adaptation of the computational 
simulator described in Chapter 2, Section 2.4, to the case of neonatal pathophysiology. 
Model equations and parameters were revised to represent the particular physiological 
characteristics of neonatal patients. The adapted model was matched to new data 
obtained from mechanically ventilated patients in the Neonatal Intensive Care Unit of 
Nottingham University Hospitals and is shown to accurately reproduce the values of key 
physiological parameters. This new model constitutes the first detailed computational 
simulator specifically tailored to neonatal ICU patients, and can be used as an 
investigational tool for developing and evaluating novel therapeutic strategies, as well as 
for developing future closed-loop ventilation modes for this patient group. 
6.2. Introduction 
Along with the administration of antepartum corticosteroids and replacement surfactant 
therapy, mechanical ventilation to provide lifesaving support for infants with respiratory 
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failure has been a key factor in improving neonatal survival, especially for preterm 
infants born before 30 weeks’ gestation with immature lung function. Mechanical 
ventilation of neonatal intensive care unit (NICU) patients is common - according to 
the SUPPORT trial (Study to Understand Prognoses and Preferences for Outcomes and 
Risks of Treatment), more than 80% of premature neonates (<28 weeks gestation) 
require invasive ventilation at some point, due to a number of reasons (e.g. poor gas 
exchange, increased work of breathing, apnoea of prematurity and/or the need for 
surfactant-replacement therapy) [186]. Although mechanical ventilation can be 
lifesaving, it may also cause lung injury resulting in bronchopulmonary dysplasia (BPD), 
a major complication of prematurity with an incident rate of 31% for babies born at 
<32 weeks gestation [187] (when babies still need mechanical ventilation at their original 
due dates, RDS is also considered as BPD). As a result, significant efforts have been 
made to develop new treatment strategies, including the use of early continuous positive 
airway pressure (CPAP) in preterm infants at risk of neonatal respiratory distress 
syndrome (RDS), and strategies for neonatal ventilator care to maintain adequate gas 
exchange but minimize lung damage. 
These efforts have been hampered by a number of factors. Ventilated, critically ill 
newborn babies are prone to sudden and large changes in their respiratory state, 
requiring frequent and rapid interventions by skilled but busy ICU staff.  If not acted on 
promptly, these can increase the risk of brain injury or eye disorders resulting in long-
term disabilities and blindness. Tight physiological control of parameters such as arterial 
oxygen partial pressure (too low increases mortality, too high risks sight loss) and 
arterial carbon dioxide partial pressure (too low risks brain injury, too high risks 
inducing intracranial hemorrhage, consciousness alterations, cataphora, and 
hyperspasmia) is essential to reduce these risks. For example, the recently completed 
Boost II trial [188] demonstrated that failure to keep premature infants in a tight oxygen 
saturation window (91-95%) increased mortality (greater time spent <91%) or blindness 
and chronic lung disease (greater time spent >95%). However, maintaining these strict 
targets is labour-intensive and, in that study, was achieved only 40% of the time [189]. 
Closed-loop ventilation control modes might offer a solution to these problems. Such 
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technologies are now available for adult patients on some ventilators, e.g. 
INTELLiVENT-ASVTM (Hamilton Medical), which automatically control ventilator 
settings such as inspired oxygen and PEEP based on clinician-guided targets and 
physiological inputs from the patient. Clinical trials on adult patients [190–192] have, so 
far, found these systems to be feasible and safe. However, there has only been a single 
study investigating the application of such technologies to paediatric patients [193], and 
the particular challenges associated with neonatal pathophysiology have so far precluded 
the application of these approaches to newborn babies. 
An additional complication is that current guidelines for the mechanical ventilation of 
neonatal patients have largely been adapted from developments in the treatment of 
adult patients, despite widespread acceptance that paediatric patients are not just “little 
adults” [194]. For example, despite its long-standing existence, neonatal respiratory 
distress syndrome remained undefined until the Montreux definition of NARDS was 
introduced in 2017 [195]. However, despite the recommendations for mechanical 
ventilation for children and neonates from PALICC, the Paediatric Mechanical 
Ventilation Consensus Conference (PEMVECC) and European Consensus Guidelines 
on management of NARDS [136, 139, 196],  reducing newborn morbidity and mortality 
still remains a significant global challenge. 
In developing countries the mortality rate in ventilated neonates due to respiratory 
distress syndrome remains high (40-60%) [197]. Furthermore, despite advances in 
intensive care, many newborn premature babies who survive RDS, go on to develop 
chronic lung disease, BPD or barotrauma as a consequence of ventilator induced lung 
injury as well as other side effects such as long-term brain injury and blindness. 
Clinician workload has been shown to be directly linked to patient outcomes [198], and 
a significant number of life-threatening human errors regularly occur (1.7 human errors 
per ICU patient per day) [199]. The number of patients undergoing mechanical 
ventilation in ICUs is expected to continue to increase (e.g. a study [200] showed that, 
overall, admission rates during the 6-year study period increased from 64.0 to 77.9 per 
Chapter 6 
 104 
1000 live births), with significant associated costs to healthcare services due to 
prolonged periods of mechanical ventilation. 
A high-fidelity computational simulator that could be shown to reproduce individual 
patient responses to changes in ventilation settings would be a valuable tool for 
evaluating novel treatment strategies, and for developing and validating closed-loop 
ventilation modes for neonatal patients. Several respiratory physiology simulators have 
been developed for adult and paediatric patients, [27, 64, 72, 73, 151], each of varying 
complexity and demonstrated validity. However, there is currently no such model 
available for neonatal subjects. This chapter introduces such a model, which has been 
adapted from the highly detailed representation of cardiorespiratory pathophysiology 
described in Chapter 2. The model has been modified to simulate neonatal patients by 
performing a detailed revision of both the model structure and parameters, as detailed 
below. 
6.3. Materials and Methods 
6.3.1. Patient selection 
To date, data have been collected from 8 neonatal patients from the neonatal intensive 
care unit of the Queen’s Medical Centre, Nottingham University Hospital, for the 
purposes of model calibration and validation as part of the NeoPredict Study (East 
Midlands NHS Ethics Committee 18/EM/0033). Patients’ gestational age ranged from 
26 to 36 weeks. An endotracheal tube (3 mm internal diameter) was used for all patients. 
The relevant patient and mechanical ventilation data are listed in Table 7. In the table, 
blood sample type C denotes capillary blood, V denotes venous blood and A denotes 
arterial blood. All patients were preterm. 
6.3.2. Simulator development and calibration to patient data 
The neonatal simulator was developed by performing a detailed revision of both the 
model structure and parameters in light of the key differences between neonatal and 
adult physiology. The extremely small volumes of neonates’ lungs, as well as their large 
respiratory and vascular resistances make simulating the neonatal respiratory system 
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challenging. Physiological features such as lung volume, cardiac output, oxygen 
consumption and airway resistance are weight-dependent in neonates, and some 
parameters such as pulmonary vascular resistance are highly variable during the first 
hours of life. The cardiac output and the volume of functional residual capacity are 
estimated in the model using the following equations [201, 202]: 
{
CO = 265 ×  weight                       weight < 1.5 (kg)
CO = 253 ×  weight           1.5 < weight < 2.5 (kg)
CO = 241 ×  weight                       weight > 2.5 (kg)
   (mL min−1) (48) 
Vfrc = (20.7 × weight) − 6.3                      (ml) (49) 
In the above, the units for CO and Vfrc are mL min-1 and mL respectively. The total 
airway resistance is notably higher in neonatal patients than in adults and decreases as 
babies grow older. This resistance is distributed between the main airway and 100 
parallel alveolar compartments in the model. Every alveolar compartment also has two 
resistances placed in series, namely the alveolar inlet resistance and the upper bronchial 
resistance. The pulmonary vascular resistance is very large during foetal life, and drops 
sharply to about 3-4 mmHg min L-1 during the first 24 hours of life as gas exchange is 
the primary function of the postnatal lung [203]. 
Both anatomical and alveolar dead spaces have been shown to increase with decreasing 
weight and gestation. Moreover, newborn babies have larger total anatomical dead space 
per kg of body weight in comparison with adults, due to the larger head to body mass 
ratio. The value of VD is 3 to 6 mL kg-1 in preterm infants weighing around 1 kg [204, 
205]. Newborn babies have a higher haemoglobin concentration compared to adults, 
with a minimum acceptable value of about 110 g L-1. This value begins to fall within the 
first week after delivery [206, 207]. Oxygen consumption in neonates is also more than 
twice that of adults on a per kg basis. There is a large rise in metabolic rate in the first 24 
hours for normal term babies; however, the rate of increase is slower in those born 
prematurely. Preterm babies also have a lower oxygen consumption rate compared with 
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term babies. The optimized value for oxygen consumption in the model is selected from 
a range of 4 to 10 mL kg-1 min-1 [208, 209]. 
Furthermore, to characterize the stiffer nature of paediatric lungs at baseline (i.e. lower 
alveolar compliance) the denominator of Eq.16 is reduced to 2000, 5000, 12000 and 
50000 cmH2O mL-2 for patients younger than 1, 1 to 2, 3 to 5 and 8 to 10 years old 
respectively. These values are obtained experimentally so that the pressure-volume 
equation of each alveolar compartment produces the appropriate level of pressures at 
the baseline, given the small tidal volumes in neonatal subjects.  
The simulator was matched to individual patient data using advanced global 
optimisation algorithms described in Chapter 3 (see Section 3.3.1). The variable model 
parameters (x) that were allowed to vary in the optimization include the three key 
alveolar features mentioned previously (Pext, k and TOP) independently for each of the 
100 alveolar compartments, as well as values for the respiratory quotient (RQ), total 
oxygen consumption, haemoglobin, volume of anatomical dead space and anatomical 
shunt. The optimization problem is formulated to find the configuration of model 










Y = [PO2, PCO2, PIP, mPaw, Pmin, TOPmean] (51) 
where Y is the vector of data values and Ŷ denotes the vector of model estimated values. 
Table 8 presents a summary of the parameters included in (x), with their dimensions and 






Table 7. The neonatal patient data and ventilator settings 
ID RR FIO2 DC PEEP VT Sample 
Type 
PO2 PCO2 Pmin PIP mPaw 
 (bpm)   (cmH2O) (mL) (kPa) (cmH2O) 
#1 47 0.21 0.24 5 4.3 C 5.2 7.0 4.7 11 6.3 
#2 45 0.21 0.29 5 4.7 V 4.4 7.5 4.6 21 9.3 
#3 40 0.21 0.26 5 6.1 C 4.9 5.4 4 29 10 
#4 50 0.21 0.25 5 5.5 C 4.1 6.8 4.9 15 7 
#5 55 0.25 0.30 7 5.5 V 4.8 7.2 6.8 20 11 
#6 61 0.27 0.31 6 5 A 8.4 5.3 5.7 20 10 
#7 50 0.21 0.23 5 6.3 A 7.8 3.9 4.7 21 11 






Table 8. Model parameters (x) used for matching patient data, dimensions and ranges 
Parameter (x) Size Range 
Pext 100 [-70,10] 
 k 100 [-2,1] 
TOP (cmH2O) 100 [5,100] 
RQ 1 [0.7,0.9] 
VO2 (mL kg-1 min-1) 1 [4,10] 
Hb (g L-1) 1 [110,200] 
Anatomical shunt (%) 1 [1,2] 






Currently, the simulator can be only matched to either venous or arterial blood gasses, 
since the blood from arterial or venous samples is fully oxygenated or deoxygenated, 
and consequently it is known at what stage to feed the data into the model. For safety 
reasons, clinicians try to avoid taking arterial or venous samples in neonatal subjects, 
preferring to use capillary blood gas values instead. However, with capillary samples, 
tissue gas exchange may not have been completed, and thus these data are more difficult 
to use for model calibration. 
Hence, only the five patients with arterial or venous blood samples have been used in 
the study at this point; all patients were diagnosed with neonatal respiratory distress 
syndrome. Patients were simulated for 30 minutes under mechanical ventilation with 
constant flow inflation and with no recruitment manoeuvre intervention. Reduced 
alveolarization was not modelled in the patients as there was no data on it, although it 
could be incorporated into the simulator by combining multiple alveolar compartments 
into one compartment. Table 9 compares the outputs of the simulations with the 
original patient data. All presented model outputs have been averaged over 1 minute. As 
shown, the simulator accurately reproduced the measured values of several key 


























Data Model Data Model Data Model Data Model Data Model 
#2 V 4.4 4.8 7.5 7.2 4.6 5.1 21 21.0 9.3 9.1 
#5 V 4.8 4.8 7.2 7.0 6.8 6.9 20 20.1 11 10.9 
#6 A 8.4 8.4 5.3 5.2 5.7 6.0 20 20.1 10 9.9 
#7 A 7.8 7.7 3.9 3.9 4.7 5.0 21 21.2 11 10.9 
#8 A 6.4 6.4 4.3 4.3 4.6 5.5 18 18.1 7.9 7.7 
 
The model was demonstrated to accurately reproduce the available clinical data for five preterm 




The first results from the development of a detailed, highly-fidelity computational 
simulator of neonatal cardiorespiratory physiology have been presented. The model was 
demonstrated to accurately reproduce the available clinical data for five preterm 
neonatal patients with measurements of arterial or venous blood gas values – data from 
several more patients is currently being collected and will be incorporated in any future 
studies. As it is refined and developed, this model will provide a novel and useful tool 
for investigating novel treatment strategies, improving recommendations and guidelines 
for choosing ventilator settings, and developing closed-loop ventilation control modes 
that are specifically tailored to neonates. 
Capillary gas tensions (and pH) always lie somewhere between the arterial values and the 
local venous values. The problem is that how close the CBG is to the ABG is 
unpredictable. High local flow, or low local metabolism can ‘arterialise’ the values, while 
poor flow or high local oxygen consumption can make the values more like central 
venous values. Some of that concern is theoretical, since CBG tend to be taken from 
tissues of low metabolic activity (i.e. skin). The other issue is that some values change a 
lot between arterial and venous blood (e.g. PO2, particularly when supplemental oxygen 
is given, such that PaO2 is high), while some values only change a little (e.g. PCO2). 
Future work will focus on incorporating physiologically realistic representations of 
capillary blood characteristics into the model, which will significantly increase the 
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Conclusions and future work 
It is widely accepted that modification of existing approaches to mechanical ventilation 
to incorporate novel treatment strategies could reduce pulmonary injury, cardiovascular 
impairment, and mortality rates, particularly if combined with novel pharmaceuticals. To 
date, however, the complex and often opaque dynamical interactions of the alveoli, 
airways, chest wall, heart and blood vessels has severely limited progress towards the 
development of therapeutic strategies optimised to specific diseases and individual. 
Critically ill patients are routinely monitored in great detail, providing extensive, high 
quality data-streams for model design & configuration and patient-matching. Models 
based on these datasets can incorporate very complex system dynamics that may be 
validated against responses of individual patients, for use as investigational surrogates. 
In contrast to trials on animal models and humans, in silico models of individualised 
patient and disease pathology are completely configurable, reproducible and reusable – 
different treatments, or combinations of treatments, can be applied to the same patient 
or subset of virtual patients, in order to understand mode of action, quantitatively 
compare effectiveness in various scenarios, and optimise interventions for particular 
clinical objectives and particular patient groups (or individuals).  
This thesis has presented work advancing research in this area on several fronts. 
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Chapter 3 investigated the efficacy of a modulator of soluble guanylate cyclase in COPD 
patients with PH by using computer simulation. In this study, close matching of the 
simulator to data on three patients was demonstrated. Calculations of blood gas 
concentrations for these virtual patients, considering the observed temporal profile of 
average PVR changes after oral administration of Riociguat (Bayer), resulted in 
predictions of changes in PaO2 and PaCO2 that were consistent with those observed in 
the previous clinical study. These results can be considered as a validation of the 
capability of the pulmonary simulator to reliably describe the effects on gas exchange of 
compounds acting on the vascular resistance, in particular those stimulating sGC 
activity. Additional validations can be achieved by confirmation of the outcomes in a 
clinical trial. Furthermore, this study showed that administering an sGC via dry powder 
inhalation can reduce pulmonary hypertension without deteriorating oxygenation, 
particularly when administration is combined with exercise. These results highlight the 
potential advantages of administering sGC’s to patients via dry powder inhalation, 
rather than systemically. 
Analysis of an extensive database on PARDS patients in Chapter 4 suggested patients 
may be being routinely over-ventilated, and that there is scope for achieving more 
protective ventilation without compromising gas exchange. The results suggest that 
interventions based on (i) progressively lowering VT while maintaining constant MinV, 
and (ii) adjusting PEEP and VT to reduce ΔP, can produce significant reductions in 
multiple key parameters associated with VILI without compromising safety. Such 
interventions could be readily implemented at the bedside by clinicians directly (similar 
to recruitment manoeuvres), or automatically via closed-loop control algorithms in next-
generation ventilators, although actual implementation will require a prospective trial. 
Although previous studies of the effects of lowering VT in PARDS have yielded 
inconclusive results, our results indicate that such strategies can be implemented safely, 
supporting the design of true randomized trials to better delineate the role of low tidal 
volume ventilation in PARDS. Finally, the results suggest a number of other potentially 
beneficial interventions which could also be evaluated in future simulation and in vivo 
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studies, including minimizing RR by using a long inspiratory time, and minimizing strain 
rate either by reducing inspiratory flow or by increasing FRC through adding PEEP. 
In Chapter 5, novel ventilatory strategies were identified that minimized ∆P, MP, and 
MMP in datasets from adults and children with ARDS. The identified strategies were 
consistent within each patient group, and were similar in both adults and children, 
suggesting that protective ventilatory strategies derived from studies in adults may have 
utility in children with ARDS. Minimising MP resulted in the use of higher VT; since this 
contradicts the current consensus on using lower VT it raises questions regarding the use 
of MP as a direct target to minimize VILI, at least as currently formulated. Although, it 
should be noted that lowering MP could generally be possible by lowering VT, but the 
lowest value of MP is associated with use of higher VT which suggests ∆P is a better 
target to be minimised rather than MP. Overall, these findings demonstrate the 
limitations of ventilatory strategies that target either ∆P or MP, highlighting the need to 
continue to refine these targets, and for ultimate validation of these strategies in clinical 
trials. 
Chapter 6 presented the development of the first detailed computational simulator 
capable of modelling neonatal respiratory physiology in the RDS disease state. The 
preliminary results of matching the model to the data collected from the Queen’s 
Medical Centre indicate that all the available clinical data on the responses of individual 
patients to a range of different ventilator settings are accurately reproduced by the 
model. The application of this model to investigate novel treatment strategies could 
make an important contribution to the field, in terms of obtaining better understanding 
of the disease, evaluating different treatment strategies such as recruitment manoeuvres 
and improving recommendations and guidelines for choosing ventilator settings. Using 
the simulator, multi-intervention treatment strategies for specific clinical objectives can 
be simulated and evaluated in a safe, and cost-efficient manner. The simulation model 
can be used for investigating alternative ventilator settings that could lower that risk of 
VILI. Drug intervention effects can also be integrated into the model. These questions 
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